Agile delivery of protein therapeutics to CNS

Journal of Controlled Release

Volumn 190, Issue , 2014, Pages 637-663

  Yi, Xiang ^a   Manickam, Devika S ^a   Brynskikh, Anna ^b   Kabanov, Alexander V ^a,c  

^a University of North Carolina at Chapel Hill   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c MOSCOW STATE UNIVERSITY   (Russian Federation)

Author keywords

Administration route; Blood brain barrier; Brain delivery; Central nervous system; Protein delivery; Protein therapeutics

Indexed keywords

BIOCHEMISTRY; BLOOD; CHEMICAL MODIFICATION; NEUROPHYSIOLOGY;

BLOOD-BRAIN BARRIER; BRAIN DELIVERY; CENTRAL NERVOUS SYSTEMS; PROTEIN DELIVERY; PROTEIN THERAPEUTICS;

PROTEINS;

ANGIOPEPTIN; BRAIN DERIVED NEUROTROPHIC FACTOR; FATTY ACID; FIBROBLAST GROWTH FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; IDURONATE 2 SULFATASE; INSULIN GLULISINE; INSULIN RECEPTOR; LIPOSOME; LOW DENSITY LIPOPROTEIN RECEPTOR; LYSOSOME ENZYME; MACROGOL; NANOPARTICLE; NERVE GROWTH FACTOR; NEUROTROPHIN 3; OXYTOCIN; POLOXAMER; POLYPROPYLENE; POLYSIALIC ACID; PROTEIN; RAP PROTEIN; VASOPRESSIN; ANGIOPEP; APROTININ; BLOCK IONOMER COMPLEX; CYCLOHEXYL(PHENYL)(2 PIPERIDINOETHYL)SILANOL; DRUG CARRIER; INSULIN RECEPTOR ANTIBODY; IRON BINDING PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MEGALIN; MTF PROTEIN; PEPTIDE; POLY(BUTYLCYANOACRYLATE) NANOPARTICLE; POLYGLACTIN; POLYMER; RECEPTOR ANTIBODY; TRANSFERRIN RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ACYLATION; ALZHEIMER DISEASE; ARTICLE; ASTROCYTOMA; BLOOD BRAIN BARRIER; BRAIN CAPILLARY ENDOTHELIAL CELL; BRAIN METASTASIS; CELL DEATH; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; CEREBROVASCULAR ACCIDENT; CIRCULATION TIME; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG PENETRATION; ENDOCYTOSIS; ENZYME REPLACEMENT; FABRY DISEASE; GAUCHER DISEASE; GLYCOGEN STORAGE DISEASE TYPE 2; HIV ASSOCIATED DEMENTIA; HUMAN; LEUKODYSTROPHY; MACROMOLECULE; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN MODIFICATION; SUBSTANTIA NIGRA PARS COMPACTA; TRANSCYTOSIS; TRAUMATIC BRAIN INJURY; BONE MARROW DERIVED MACROPHAGE; CATIONIZATION; CENTRAL NERVOUS SYSTEM DELIVERY; CENTRAL NERVOUS SYSTEM DISEASE; DRUG ADMINISTRATION ROUTE; DRUG CONJUGATION; DRUG IMPLANTATION; FATTY ACID ACYLATION; INTRAPARENCHYMAL DRUG ADMINISTRATION; LIPOSOMAL DELIVERY; MULTICENTER STUDY (TOPIC); NEUROPATHOLOGY; NEUROPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; CENTRAL NERVOUS SYSTEM DISEASES; PATHOLOGY; PHYSIOLOGY;

BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM DISEASES; DRUG CARRIERS; HUMANS; NANOPARTICLES; PEPTIDES; PROTEINS;

EID: 84906782339     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.06.017     Document Type: Review

References (467)

1. I. Tof Recombinant DNA technology in the synthesis of human insulin 1994 Little Tree Publishing
2. B. Leader, Q.J. Baca, and D.E. Golan Protein therapeutics: a summary and pharmacological classification Nat. Rev. 7 2008 21 39
3. F.M. Veronese, and J.M. Harris Introduction and overview of peptide and protein pegylation Adv. Drug Deliv. Rev. 54 2002 453 456 (Pubitemid 34615541)
4. F. Danhier, E. Ansorena, J.M. Silva, R. Coco, A. Le Breton, and V. Preat PLGA-based nanoparticles: an overview of biomedical applications J. Control. Release 161 2012 505 522
5. K.M. Kulasa The current status of exenatide once weekly Clin. Med. Insights Ther. 3 2011 221 232
6. C.L. Willis, T.A. Brooks, and T.P. Davis Chronic inflammatory pain and the neurovascular unit: a central role for glia in maintaining BBB integrity? Curr. Pharm. Des. 14 2008 1625 1643 (Pubitemid 352002991)
7. W. Pan, and A.J. Kastin Cytokine transport across the injured blood-spinal cord barrier Curr. Pharm. Des. 14 2008 1620 1624 (Pubitemid 352002990)
8. A.J. Kastin, and W. Pan Blood-brain barrier and feeding: regulatory roles of saturable transport systems for ingestive peptides Curr. Pharm. Des. 14 2008 1615 1619 (Pubitemid 352002989)
9. W.A. Banks The blood-brain barrier as a cause of obesity Curr. Pharm. Des. 14 2008 1606 1614 (Pubitemid 352002988)
10. R. Deane, A. Sagare, and B.V. Zlokovic The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer's disease Curr. Pharm. Des. 14 2008 1601 1605 (Pubitemid 352002987)
11. J.D. Huber Diabetes, cognitive function, and the blood-brain barrier Curr. Pharm. Des. 14 2008 1594 1600 (Pubitemid 352002986)
12. P. Dore-Duffy Pericytes: pluripotent cells of the blood brain barrier Curr. Pharm. Des. 14 2008 1581 1593 (Pubitemid 352002985)
13. D.J. Begley, C.C. Pontikis, and M. Scarpa Lysosomal storage diseases and the blood-brain barrier Curr. Pharm. Des. 14 2008 1566 1580 (Pubitemid 352002984)
14. B. Engelhardt The blood-central nervous system barriers actively control immune cell entry into the central nervous system Curr. Pharm. Des. 14 2008 1555 1565 (Pubitemid 352002983)
15. W.A. Banks The blood-brain barrier as a cause of disease Curr. Pharm. Des. 14 2008 1553 1554
16. E. Paul Das Sauerstoff-Bedurfnis des Organismus: Eine Farbenanalytische Studie 1885 Hirschwald Berlin
17. E.E. Goldmann Vitalfarbung am Zentralnervensystem Abh. Preuss. Akad. Wiss. Phys. Math. K1 1 1913 1 60
18. T.S. Reese, and M.J. Karnovsky Fine structural localization of a blood-brain barrier to exogenous peroxidase J. Cell Biol. 34 1967 207 217
19. M.J. Karnovsky The ultrastructural basis of capillary permeability studied with peroxidase as a tracer J. Cell Biol. 35 1967 213 236
20. L.L. Rubin, and J.M. Staddon The cell biology of the blood-brain barrier Ann. Rev. Neurosci. 22 1999 11 28 (Pubitemid 29144879)
21. M. Ramsauer Pericytes and their contribution to the blood-brain barrier D.C.S.A.M.N. Rolf Dermietzel, David C. Spray, Maiken Nedergaard, Blood-brain Barriers, From Ontogeny to Artificial Interfaces 2006 Wiley-VCH 29
22. S.M. Frederic Mercier, and Glenn I. Hatton Brain microphages: enigmas and conundrums D.C.S.A.M.N. Rolf Dermietzel, David C. Spray, Maiken Nedergaard, Blood-brain Barriers, From Ontogeny to Artificial Interfaces 2006 WILEY-VCH 37
23. B.T. Hawkins, and T.P. Davis The blood-brain barrier/neurovascular unit in health and disease Pharmacol. Rev. 57 2005 173 185 (Pubitemid 41043883)
24. W.A. Banks Drug delivery to the brain in Alzheimer's disease: consideration of the blood-brain barrier Adv. Drug Deliv. Rev. 64 2012 629 639
25. O.O. Ogunshola, and A. Al-Ahmad HIF-1 at the blood-brain barrier: a mediator of permeability? High Alt. Med. Biol. 13 2012 153 161
26. C. Kaur, and E.A. Ling Blood brain barrier in hypoxic-ischemic conditions Curr. Neurovasc. Res. 5 2008 71 81 (Pubitemid 351302657)
27. M. Fiala, L. Zhang, X. Gan, B. Sherry, D. Taub, M.C. Graves, S. Hama, D. Way, M. Weinand, M. Witte, D. Lorton, Y.M. Kuo, and A.E. Roher Amyloid-beta induces chemokine secretion and monocyte migration across a human blood-brain barrier model Mol. Med. 4 1998 480 489 (Pubitemid 28419092)
28. A. Rosell, E. Cuadrado, A. Ortega-Aznar, M. Hernandez-Guillamon, E.H. Lo, and J. Montaner MMP-9-positive neutrophil infiltration is associated to blood-brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke Stroke 39 2008 1121 1126 (Pubitemid 351440679)
29. K. Scholler, A. Trinkl, M. Klopotowski, S.C. Thal, N. Plesnila, R. Trabold, G.F. Hamann, R. Schmid-Elsaesser, and S. Zausinger Characterization of microvascular basal lamina damage and blood-brain barrier dysfunction following subarachnoid hemorrhage in rats Brain Res. 1142 2007 237 246 (Pubitemid 46413192)
30. C. Nicaise, D. Mitrecic, P. Demetter, R. De Decker, M. Authelet, A. Boom, and R. Pochet Impaired blood-brain and blood-spinal cord barriers in mutant SOD1-linked ALS rat Brain Res. 1301 2009 152 162
31. L. Claudio Ultrastructural features of the blood-brain barrier in biopsy tissue from Alzheimer's disease patients Acta Neuropathol. 91 1996 6 14
32. D.W. Williams, E.A. Eugenin, T.M. Calderon, and J.W. Berman Monocyte maturation, HIV susceptibility, and transmigration across the blood brain barrier are critical in HIV neuropathogenesis J. Leukoc. Biol. 91 2012 401 415
33. A. Kondo, and K. Suzuki The blood brain barrier in human leukodystrophies and allied diseases. Ultrastructural and morphometric studies on the capillaries in brain biopsies Clin. Neuropathol. 12 1993 169 174 (Pubitemid 23176564)
34. G. Tsurita, H. Nagawa, S. Ueno, S. Watanabe, and M. Taki Biological and morphological effects on the brain after exposure of rats to a 1439 MHz TDMA field Bioelectromagnetics 21 2000 364 371
35. D.S. Miller, B. Bauer, and A.M. Hartz Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy Pharmacol. Rev. 60 2008 196 209 (Pubitemid 351962009)
36. W.A. Banks, A.J. Kastin, W. Huang, J.B. Jaspan, and L.M. Maness Leptin enters the brain by a saturable system independent of insulin Peptides 17 1996 305 311 (Pubitemid 26124406)
37. W.A. Banks, C.R. DiPalma, and C.L. Farrell Impaired transport of leptin across the blood-brain barrier in obesity Peptides 20 1999 1341 1345
38. W.A. Banks, and C.L. Farrell Impaired transport of leptin across the blood-brain barrier in obesity is acquired and reversible Am. J. Physiol. Endocrinol. Metab. 285 2003 E10 E15
39. A.J. Kastin, W. Pan, L.M. Maness, R.J. Koletsky, and P. Ernsberger Decreased transport of leptin across the blood-brain barrier in rats lacking the short form of the leptin receptor Peptides 20 1999 1449 1453 (Pubitemid 30069891)
40. S.M. Hileman, D.D. Pierroz, H. Masuzaki, C. Bjorbaek, K. El-Haschimi, W.A. Banks, and J.S. Flier Characterizaton of short isoforms of the leptin receptor in rat cerebral microvessels and of brain uptake of leptin in mouse models of obesity Endocrinology 143 2002 775 783 (Pubitemid 34164025)
41. P.G. Ravenstijn, H.J. Drenth, M.J. O'Neill, M. Danhof, and E.C. de Lange Evaluation of blood-brain barrier transport and CNS drug metabolism in diseased and control brain after intravenous L-DOPA in a unilateral rat model of Parkinson's disease Fluids Barriers CNS 9 2012 4
42. M. Marsala, I. Vanicky, J. Tokumine, O. Kakinohana, and J. Marsala Blood-brain barrier changes in global and focal cerebral ischemia H.S.S.A.J. Hari Shanker Sharma, Jan Westman, Blood-spinal Cord and Brain Barriers in Health and Disease 2004 Elsiver Academic Press 385 386
43. E. Preston, and J. Webster Differential passage of [14C]sucrose and [3H]inulin across rat blood-brain barrier after cerebral ischemia Acta Neuropathol. 103 2002 237 242 (Pubitemid 36075324)
44. T.N. Nagaraja, K.A. Keenan, J.D. Fenstermacher, and R.A. Knight Acute leakage patterns of fluorescent plasma flow markers after transient focal cerebral ischemia suggest large openings in blood-brain barrier Microcirculation 15 2008 1 14
45. T.N. Nagaraja, J.R. Ewing, K. Karki, P.E. Jacobs, G.W. Divine, J.D. Fenstermacher, C.S. Patlak, and R.A. Knight MRI and quantitative autoradiographic studies following bolus injections of unlabeled and (14)C-labeled gadolinium-diethylenetriaminepentaacetic acid in a rat model of stroke yield similar distribution volumes and blood-to-brain influx rate constants NMR Biomed. 24 2011 547 558
46. G.J. Badaut Bix, Vascular neural network phenotypic transformation after traumatic injury: potential role in long-term sequelae Translational stroke research 5 2014 394 406
47. M. Kuntz, C. Mysiorek, O. Petrault, M. Petrault, R. Uzbekov, R. Bordet, L. Fenart, R. Cecchelli, and V. Berezowski Stroke-induced brain parenchymal injury drives blood-brain barrier early leakage kinetics: a combined in vivo/in vitro study J. Cereb. Blood Flow Metab. 34 2014 95 107
48. A. Jullienne, and J. Badaut Molecular contributions to neurovascular unit dysfunctions after brain injuries: lessons for target-specific drug development Futur. Neurol. 8 2013 677 689
49. A.K. Saenger, and R.H. Christenson Stroke biomarkers: progress and challenges for diagnosis, prognosis, differentiation, and treatment Clin. Chem. 56 2010 21 33
50. S.W. Lee, W.J. Kim, J.A. Park, Y.K. Choi, Y.W. Kwon, and K.W. Kim Blood-brain barrier interfaces and brain tumors Arch. Pharm. Res. 29 2006 265 275 (Pubitemid 43685278)
51. S. Feng, J. Cen, Y. Huang, H. Shen, L. Yao, Y. Wang, and Z. Chen Matrix metalloproteinase-2 and -9 secreted by leukemic cells increase the permeability of blood-brain barrier by disrupting tight junction proteins PLoS ONE 6 2011 e20599
52. H.M. Wisniewski, R. Pluta, A.S. Lossinsky, and M.J. Mossakowski Ultrastructural studies of cerebral vascular spasm after cardiac arrest-related global cerebral ischemia in rats Acta Neuropathol. 90 1995 432 440
53. M.J. Cipolla, R. Crete, L. Vitullo, and R.D. Rix Transcellular transport as a mechanism of blood-brain barrier disruption during stroke Front. Biosci. 9 2004 777 785 (Pubitemid 39043750)
54. S. Craft, L.D. Baker, T.J. Montine, S. Minoshima, G.S. Watson, A. Claxton, M. Arbuckle, M. Callaghan, E. Tsai, S.R. Plymate, P.S. Green, J. Leverenz, D. Cross, and B. Gerton Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial Arch. Neurol. 69 2012 29 38
55. S. Craft, B. Cholerton, and L.D. Baker Insulin and Alzheimer's disease: untangling the web J. Alzheimers Dis. 33 Suppl 1 2013 S263 S275
56. J. Freiherr, M. Hallschmid, W.H. Frey II, Y.F. Brunner, C.D. Chapman, C. Holscher, S. Craft, F.G. De Felice, and C. Benedict Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence CNS Drugs 27 2013 505 514
57. I. Gantz, N. Erondu, M. Mallick, B. Musser, R. Krishna, W.K. Tanaka, K. Snyder, C. Stevens, M.A. Stroh, H. Zhu, J.A. Wagner, D.J. Macneil, S.B. Heymsfield, and J.M. Amatruda Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults J. Clin. Endocrinol. Metab. 92 2007 1754 1757 (Pubitemid 46997183)
58. M.C. Rattazzi, and K. Dobrenis Treatment of GM2 gangliosidosis: past experiences, implications, and future prospects Adv. Genet. 44 2001 317 339 (Pubitemid 33804462)
59. B.U. von Specht, B. Geiger, R. Arnon, J. Passwell, G. Keren, B. Goldman, and B. Padeh Enzyme replacement in Tay-Sachs disease Neurology 29 1979 848
60. Shire Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment (AIM-IT) ClinicalTrials.gov 2014
61. P. Calias, M. Papisov, J. Pan, N. Savioli, V. Belov, Y. Huang, J. Lotterhand, M. Alessandrini, N. Liu, A.J. Fischman, J.L. Powell, and M.W. Heartlein CNS penetration of intrathecal-lumbar idursulfase in the monkey, dog and mouse: implications for neurological outcomes of lysosomal storage disorder PLoS ONE 7 2012 e30341
62. M. Eriksdotter Jonhagen, A. Nordberg, K. Amberla, L. Backman, T. Ebendal, B. Meyerson, L. Olson, Seiger, M. Shigeta, E. Theodorsson, M. Viitanen, B. Winblad, and L.O. Wahlund Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease Dement. Geriatr. Cogn. Disord. 9 1998 246 257 (Pubitemid 28377225)
63. J.G. Nutt, K.J. Burchiel, C.L. Comella, J. Jankovic, A.E. Lang, E.R. Laws Jr., A.M. Lozano, R.D. Penn, R.K. Simpson Jr., M. Stacy, and G.F. Wooten Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD Neurology 60 2003 69 73 (Pubitemid 36070646)
64. A.E. Lang, S. Gill, N.K. Patel, A. Lozano, J.G. Nutt, R. Penn, D.J. Brooks, G. Hotton, E. Moro, P. Heywood, M.A. Brodsky, K. Burchiel, P. Kelly, A. Dalvi, B. Scott, M. Stacy, D. Turner, V.G. Wooten, W.J. Elias, E.R. Laws, V. Dhawan, A.J. Stoessl, J. Matcham, R.J. Coffey, and M. Traub Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease Ann. Neurol. 59 2006 459 466 (Pubitemid 43358066)
65. M.F. Salvatore, Y. Ai, B. Fischer, A.M. Zhang, R.C. Grondin, Z. Zhang, G.A. Gerhardt, and D.M. Gash Point source concentration of GDNF may explain failure of phase II clinical trial Exp. Neurol. 202 2006 497 505 (Pubitemid 44692690)
66. S. Kalra, A. Genge, and D.L. Arnold A prospective, randomized, placebo-controlled evaluation of corticoneuronal response to intrathecal BDNF therapy in ALS using magnetic resonance spectroscopy: feasibility and results Amyotroph. Lateral Scler. Other Mot. Neuron Disord. 4 2003 22 26 (Pubitemid 36636909)
67. M. Beck, P. Flachenecker, T. Magnus, R. Giess, K. Reiners, K.V. Toyka, and M. Naumann Autonomic dysfunction in ALS: a preliminary study on the effects of intrathecal BDNF Amyotroph. Lateral Scler. Other Mot. Neuron Disord. 6 2005 100 103 (Pubitemid 40903539)
68. C.A. Boswell, and M.W. Brechbiel Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view Nucl. Med. Biol. 34 2007 757 778 (Pubitemid 47503817)
69. Convection-enhanced delivery of 124I-8H9 for patients with non-progressive diffuse pontine gliomas previously treated with external beam radiation therapy 2014
70. DDAVP Nasal Spray 2014 RxList Inc. (http://www.rxlist.com/ddavp-nasal- spray-drug/indications-dosage.htm)
71. D. De Berardis, S. Marini, F. Iasevoli, C. Tomasetti, A. de Bartolomeis, M. Mazza, A. Valchera, M. Fornaro, M. Cavuto, V. Srinivasan, G. Sepede, G. Martinotti, and M. Di Giannantonio The role of intranasal oxytocin in the treatment of patients with schizophrenia: a systematic review CNS Neurol. Disord. Drug Targets 12 2013 252 264
72. M.C. Davis, J. Lee, W.P. Horan, A.D. Clarke, M.R. McGee, M.F. Green, and S.R. Marder Effects of single dose intranasal oxytocin on social cognition in schizophrenia Schizophr. Res. 147 2013 393 397
73. M.R. Lee, H.J. Wehring, R.P. McMahon, J. Linthicum, N. Cascella, F. Liu, A. Bellack, R.W. Buchanan, G.P. Strauss, C. Contoreggi, and D.L. Kelly Effects of adjunctive intranasal oxytocin on olfactory identification and clinical symptoms in schizophrenia: results from a randomized double blind placebo controlled pilot study Schizophr. Res. 145 2013 110 115
74. M.J. Bakermans-Kranenburg, and I.J.M.H. van Sniffing around oxytocin: review and meta-analyses of trials in healthy and clinical groups with implications for pharmacotherapy Transl. Psychiatry 3 2013 e258
75. A. Preti, M. Melis, S. Siddi, M. Vellante, G. Doneddu, and R. Fadda Oxytocin and autism: a systematic review of randomized controlled trials J. Child Adolesc. Psychopharmacol. 24 2014 54 68
76. G.J. Sanger, and K. Lee Hormones of the gut-brain axis as targets for the treatment of upper gastrointestinal disorders Nat. Rev. 7 2008 241 254 (Pubitemid 351321235)
77. W.A. Banks, S.A. Farr, and J.E. Morley The effects of high fat diets on the blood-brain barrier transport of leptin: failure or adaptation? Physiol. Behav. 88 2006 244 248
78. W.A. Banks, A. Gertler, G. Solomon, L. Niv-Spector, M. Shpilman, X. Yi, E. Batrakova, S. Vinogradov, and A.V. Kabanov Principles of strategic drug delivery to the brain (SDDB): development of anorectic and orexigenic analogs of leptin Physiol. Behav. 105 2011 145 149
79. T.A. Ratko, A. Marbella, S. Godfrey, and N. Aronson Enzyme-Replacement Therapies for Lysosomal Storage Diseases 2013 (Rockville MD)
80. C. Hawkes, and S. Kar The insulin-like growth factor-II/mannose-6- phosphate receptor: structure, distribution and function in the central nervous system Brain Res. Brain Res. Rev. 44 2004 117 140 (Pubitemid 38293429)
81. A. Urayama, J.H. Grubb, W.S. Sly, and W.A. Banks Mannose 6-phosphate receptor-mediated transport of sulfamidase across the blood-brain barrier in the newborn mouse Mol. Ther. 16 2008 1261 1266 (Pubitemid 351866057)
82. A. Urayama, J.H. Grubb, W.A. Banks, and W.S. Sly Epinephrine enhances lysosomal enzyme delivery across the blood brain barrier by up-regulation of the mannose 6-phosphate receptor Proc. Natl. Acad. Sci. U. S. A. 104 2007 12873 12878
83. A. Urayama, J.H. Grubb, W.S. Sly, and W.A. Banks Developmentally regulated mannose 6-phosphate receptor-mediated transport of a lysosomal enzyme across the blood-brain barrier Proc. Natl. Acad. Sci. U. S. A. 101 2004 12658 12663 (Pubitemid 39122079)
84. P.H. Schlesinger, J.S. Rodman, T.W. Doebber, P.D. Stahl, Y.C. Lee, C.P. Stowell, and T.B. Kuhlenschmidt The role of extra-hepatic tissues in the receptor-mediated plasma clearance of glycoproteins terminated by mannose or N-acetylglucosamine Biochem. J. 192 1980 597 606 (Pubitemid 11206830)
85. R.G. Thorne, and W.H. Frey II Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations Clin. Pharmacokinet. 40 2001 907 946 (Pubitemid 34066688)
86. W. Pan, W.A. Banks, and A.J. Kastin Permeability of the blood-brain barrier to neurotrophins Brain Res. 788 1998 87 94 (Pubitemid 28202147)
87. W. Pan, W.A. Banks, M.B. Fasold, J. Bluth, and A.J. Kastin Transport of brain-derived neurotrophic factor across the blood-brain barrier Neuropharmacology 37 1998 1553 1561 (Pubitemid 28550429)
88. J.H. Kordower, S. Palfi, E.Y. Chen, S.Y. Ma, T. Sendera, E.J. Cochran, E.J. Cochran, E.J. Mufson, R. Penn, C.G. Goetz, and C.D. Comella Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease Ann. Neurol. 46 1999 419 424 (Pubitemid 29416283)
89. Y.H. Kim, H. Nagai, H. Ozasa, Y. Sakamori, and M. Mishima Therapeutic strategy for non-small-cell lung cancer patients with brain metastases (Review) Biomed. Rep. 1 2013 691 696
90. O. Kuittinen, T. Siniluoto, M. Isokangas, T. Turpeenniemi-Hujanen, J. Peltonen, S. Alahuhta, and E. Sonkajarvi Chemotherapy in conjunction with blood brain barrier disruption in the treatment of primary central nervous system lymphoma Duodecim 129 2013 1563 1570
91. N.Y. Hernandez-Pedro, E. Rangel-Lopez, G. Vargas Felix, B. Pineda, and J. Sotelo An update in the use of antibodies to treat glioblastoma multiforme Autoimmune Dis. 2013 2013 716813
92. B. Winblad, A. Graf, M.E. Riviere, N. Andreasen, and J.M. Ryan Active immunotherapy options for Alzheimer's disease Alzheimers Res. Ther. 6 2014 7
93. L. Lannfelt, N.R. Relkin, and E.R. Siemers Amyloid-ss-directed immunotherapy for Alzheimer's disease J. Intern. Med. 275 2014 284 295
94. J.F. Poduslo, M. Ramakrishnan, S.S. Holasek, M. Ramirez-Alvarado, K.K. Kandimalla, E.J. Gilles, G.L. Curran, and T.M. Wengenack In vivo targeting of antibody fragments to the nervous system for Alzheimer's disease immunotherapy and molecular imaging of amyloid plaques J. Neurochem. 102 2007 420 433 (Pubitemid 47007650)
95. K.A. Witt, T.J. Gillespie, J.D. Huber, R.D. Egleton, and T.P. Davis Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability Peptides 22 2001 2329 2343
96. C. Chen, and G.M. Pollack Altered disposition and antinociception of [D-penicillamine(2,5)] enkephalin in mdr1a-gene-deficient mice J. Pharmacol. Exp. Ther. 287 1998 545 552 (Pubitemid 29133652)
97. C.A. Del Vecchio, G. Li, and A.J. Wong Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas Expert Rev. Vaccines 11 2012 133 144
98. A.B. Heimberger, and J.H. Sampson The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients Expert opinion on biological therapy 9 2009 1087 1098
99. D. Ha, D.K. Stone, R.L. Mosley, and H.E. Gendelman Immunization strategies for Parkinson's disease Parkinsonism Relat. Disord. 18 Suppl. 1 2012 S218 S221
100. A. Schneeberger, M. Mandler, F. Mattner, and W. Schmidt Vaccination for Parkinson's disease Parkinsonism Relat. Disord. 18 Suppl. 1 2012 S11 S13
101. R.U. Agu, M.I. Ugwoke, M. Armand, R. Kinget, and N. Verbeke The lung as a route for systemic delivery of therapeutic proteins and peptides Respir. Res. 2 2001 198 209 (Pubitemid 34187927)
102. G. Scheuch, M.J. Kohlhaeufl, P. Brand, and R. Siekmeier Clinical perspectives on pulmonary systemic and macromolecular delivery Adv. Drug Deliv. Rev. 58 2006 996 1008 (Pubitemid 44709266)
103. J.L. Selam Inhaled insulin for the treatment of diabetes: projects and devices Expert. Opin. Pharmacother. 4 2003 1373 1377
104. K. Park, I.C. Kwon, and K. Park Oral protein delivery: current status and future prospect React. Funct. Polym. 71 2011 280 287
105. R. Singh, S. Singh, and J.W. Lillard Jr. Past, present, and future technologies for oral delivery of therapeutic proteins J. Pharm. Sci. 97 2008 2497 2523
106. T. Jung, W. Kamm, A. Breitenbach, E. Kaiserling, J.X. Xiao, and T. Kissel Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake? Eur. J. Pharm. Biopharm. 50 2000 147 160 (Pubitemid 30326694)
107. D. Das, and S. Lin Double-coated poly (butylcynanoacrylate) nanoparticulate delivery systems for brain targeting of dalargin via oral administration J. Pharm. Sci. 94 2005 1343 1353 (Pubitemid 40904197)
108. S. Zhou, X. Deng, S. He, X. Li, W. Jia, D. Wei, Z. Zhang, and J. Ma Study on biodegradable microspheres containing recombinant interferon-alpha-2a J. Pharm. Pharmacol. 54 2002 1287 1292
109. W.A. Banks Are the extracellular [correction of extracelluar] pathways a conduit for the delivery of therapeutics to the brain? Curr. Pharm. Des. 10 2004 1365 1370 (Pubitemid 38559752)
110. W.A. Banks, B. Terrell, S.A. Farr, S.M. Robinson, N. Nonaka, and J.E. Morley Passage of amyloid beta protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease Peptides 23 2002 2223 2226 (Pubitemid 36092057)
111. F. Bard, C. Cannon, R. Barbour, R.L. Burke, D. Games, H. Grajeda, T. Guido, K. Hu, J. Huang, K. Johnson-Wood, K. Khan, D. Kholodenko, M. Lee, I. Lieberburg, R. Motter, M. Nguyen, F. Soriano, N. Vasquez, K. Weiss, B. Welch, P. Seubert, D. Schenk, and T. Yednock Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease Nat. Med. 6 2000 916 919 (Pubitemid 30644751)
112. D. Morgan, D.M. Diamond, P.E. Gottschall, K.E. Ugen, C. Dickey, J. Hardy, K. Duff, P. Jantzen, G. DiCarlo, D. Wilcock, K. Connor, J. Hatcher, C. Hope, M. Gordon, and G.W. Arendash A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease Nature 408 2000 982 985 (Pubitemid 32101645)
113. W.A. Banks, N.L. Jumbe, C.L. Farrell, M.L. Niehoff, and A.C. Heatherington Passage of erythropoietic agents across the blood-brain barrier: a comparison of human and murine erythropoietin and the analog darbepoetin alfa Eur. J. Pharmacol. 505 2004 93 101 (Pubitemid 39535680)
114. H. Ehrenreich, M. Hasselblatt, C. Dembowski, L. Cepek, P. Lewczuk, M. Stiefel, H.H. Rustenbeck, N. Breiter, S. Jacob, F. Knerlich, M. Bohn, W. Poser, E. Ruther, M. Kochen, O. Gefeller, C. Gleiter, T.C. Wessel, M. De Ryck, L. Itri, H. Prange, A. Cerami, M. Brines, and A.L. Siren Erythropoietin therapy for acute stroke is both safe and beneficial Mol. Med. 8 2002 495 505 (Pubitemid 36337492)
115. R.D. Broadwell, and M.V. Sofroniew Serum proteins bypass the blood-brain fluid barriers for extracellular entry to the central nervous system Exp. Neurol. 120 1993 245 263 (Pubitemid 23165019)
116. B.J. Balin, R.D. Broadwell, M. Salcman, and M. el-Kalliny Avenues for entry of peripherally administered protein to the central nervous system in mouse, rat, and squirrel monkey J. Comp. Neurol. 251 1986 260 280 (Pubitemid 16027854)
117. Y.J. Yu, Y. Zhang, M. Kenrick, K. Hoyte, W. Luk, Y. Lu, J. Atwal, J.M. Elliott, S. Prabhu, R.J. Watts, and M.S. Dennis Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target Sci. Transl. Med. 3 2011 84ra44
118. C. Vogler, B. Levy, J.H. Grubb, N. Galvin, Y. Tan, E. Kakkis, N. Pavloff, and W.S. Sly Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII Proc. Natl. Acad. Sci. U. S. A. 102 2005 14777 14782 (Pubitemid 41457132)
119. D.S. Pisal, M.P. Kosloski, and S.V. Balu-Iyer Delivery of therapeutic proteins J. Pharm. Sci. 99 2010 2557 2575
120. E.A. Nance, G.F. Woodworth, K.A. Sailor, T.Y. Shih, Q. Xu, G. Swaminathan, D. Xiang, C. Eberhart, and J. Hanes A dense poly(ethylene glycol) coating improves penetration of large polymeric nanoparticles within brain tissue Sci. Transl. Med. 4 2012 49ra119
121. M.E. Jonhagen Nerve growth factor treatment in dementia Alzheimer Dis. Assoc. Disord. 14 Suppl. 1 2000 S31 S38 (Pubitemid 30406770)
122. R.G. Blasberg, C. Patlak, and J.D. Fenstermacher Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion J. Pharmacol. Exp. Ther. 195 1975 73 83
123. E.J. Mufson, J.S. Kroin, Y.T. Liu, T. Sobreviela, R.D. Penn, J.A. Miller, and J.H. Kordower Intrastriatal and intraventricular infusion of brain-derived neurotrophic factor in the cynomologous monkey: distribution, retrograde transport and co-localization with substantia nigra dopamine-containing neurons Neuroscience 71 1996 179 191
124. Q. Yan, C. Matheson, J. Sun, M.J. Radeke, S.C. Feinstein, and J.A. Miller Distribution of intracerebral ventricularly administered neurotrophins in rat brain and its correlation with trk receptor expression Exp. Neurol. 127 1994 23 36 (Pubitemid 24199219)
125. I.A. Ferguson, J.B. Schweitzer, P.F. Bartlett, and E.M. Johnson Jr. Receptor-mediated retrograde transport in CNS neurons after intraventricular administration of NGF and growth factors J. Comp. Neurol. 313 1991 680 692
126. R.K. Jain Delivery of novel therapeutic agents in tumors: physiological barriers and strategies J. Natl. Cancer Inst. 81 1989 570 576 (Pubitemid 19104487)
127. W.M. Saltzman, M.W. Mak, M.J. Mahoney, E.T. Duenas, and J.L. Cleland Intracranial delivery of recombinant nerve growth factor: release kinetics and protein distribution for three delivery systems Pharm. Res. 16 1999 232 240 (Pubitemid 29135127)
128. R.H. Bobo, D.W. Laske, A. Akbasak, P.F. Morrison, R.L. Dedrick, and E.H. Oldfield Convection-enhanced delivery of macromolecules in the brain Proc. Natl. Acad. Sci. U. S. A. 91 1994 2076 2080 (Pubitemid 24092045)
129. W. Debinski, and S.B. Tatter Convection-enhanced delivery for the treatment of brain tumors Expert. Rev. Neurother. 9 2009 1519 1527
130. N.U. Barua, S.S. Gill, and S. Love Convection-enhanced drug delivery to the brain: therapeutic potential and neuropathological considerations Brain Pathol. 24 2014 117 127
131. W.M. Pardridge Biopharmaceutical drug targeting to the brain J. Drug Target. 18 2010 157 167
132. P. Wersall, I. Ohlsson, P. Biberfeld, V.P. Collins, S. von Krusenstjerna, S. Larsson, H. Mellstedt, and J. Boethius Intratumoral infusion of the monoclonal antibody, mAb 425, against the epidermal-growth-factor receptor in patients with advanced malignant glioma Cancer Immunol. Immunother. 44 1997 157 164 (Pubitemid 27278388)
133. R.R. Lonser, R. Schiffman, R.A. Robison, J.A. Butman, Z. Quezado, M.L. Walker, P.F. Morrison, S. Walbridge, G.J. Murray, D.M. Park, R.O. Brady, and E.H. Oldfield Image-guided, direct convective delivery of glucocerebrosidase for neuronopathic Gaucher disease Neurology 68 2007 254 261 (Pubitemid 46148336)
134. E. Allard, C. Passirani, and J.P. Benoit Convection-enhanced delivery of nanocarriers for the treatment of brain tumors Biomaterials 30 2009 2302 2318
135. J.J. Lochhead, and R.G. Thorne Intranasal delivery of biologics to the central nervous system Adv. Drug Deliv. Rev. 64 2012 614 628
136. X.Q. Chen, J.R. Fawcett, Y.E. Rahman, T.A. Ala, and I.W. Frey Delivery of nerve growth factor to the brain via the olfactory pathway J. Alzheimers Dis. 1 1998 35 44
137. R.G. Thorne, G.J. Pronk, V. Padmanabhan, and W.H. Frey II Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration Neuroscience 127 2004 481 496 (Pubitemid 38950662)
138. D.B. Renner, W.H. Frey II, and L.R. Hanson Intranasal delivery of siRNA to the olfactory bulbs of mice via the olfactory nerve pathway Neurosci. Lett. 513 2012 193 197
139. D.B. Renner, A.L. Svitak, N.J. Gallus, M.E. Ericson, W.H. Frey II, and L.R. Hanson Intranasal delivery of insulin via the olfactory nerve pathway J. Pharm. Pharmacol. 64 2012 1709 1714
140. R. Pietrowsky, A. Thiemann, W. Kern, H.L. Fehm, and J. Born A nose-brain pathway for psychotropic peptides: evidence from a brain evoked potential study with cholecystokinin Psychoneuroendocrinology 21 1996 559 572 (Pubitemid 27061944)
141. W. Kern, B. Schiefer, J. Schwarzenburg, E.F. Stange, J. Born, and H.L. Fehm Evidence for central nervous effects of corticotropin-releasing hormone on gastric acid secretion in humans Neuroendocrinology 65 1997 291 298 (Pubitemid 27152086)
142. W. Kern, J. Born, H. Schreiber, and H.L. Fehm Central nervous system effects of intranasally administered insulin during euglycemia in men Diabetes 48 1999 557 563 (Pubitemid 29106869)
143. A.J. Guastella, and C. MacLeod A critical review of the influence of oxytocin nasal spray on social cognition in humans: evidence and future directions Horm. Behav. 61 2012 410 418
144. S.L. Evans, O. Dal Monte, P. Noble, and B.B. Averbeck Intranasal oxytocin effects on social cognition: a critique Brain Res. 2013 Nov 14. 10.1016/j.brainres.2013.11.008 pii: S0006-8993(13)01503-5. [Epub ahead of print]
145. T. Lopes, J.S. Dias, J. Marcelino, J. Varela, S. Ribeiro, and J. Dias An assessment of the clinical efficacy of intranasal desmopressin spray in the treatment of renal colic BJU Int. 87 2001 322 325 (Pubitemid 32240842)
146. http://www.drugs.com/pro/desmopressin-nasal-spray.html
147. A. Theodoridou, I.S. Penton-Voak, and A.C. Rowe A direct examination of the effect of intranasal administration of oxytocin on approach-avoidance motor responses to emotional stimuli PLoS ONE 8 2013 e58113
148. Y.R. Kim, C.H. Kim, V. Cardi, J.S. Eom, Y. Seong, and J. Treasure Intranasal oxytocin attenuates attentional bias for eating and fat shape stimuli in patients with anorexia nervosa Psychoneuroendocrinology 44 2014 133 142 10.1016/j.psyneuen.2014.02.019 Epub 2014 Mar 13
149. K. Prehn, P. Kazzer, A. Lischke, M. Heinrichs, S.C. Herpertz, and G. Domes Effects of intranasal oxytocin on pupil dilation indicate increased salience of socioaffective stimuli Psychophysiology 50 2013 528 537
150. P. Riekkinen, J.J. Legros, C. Sennef, J. Jolkkonen, S. Smitz, and H. Soininen Penetration of DGAVP (Org 5667) across the blood-brain barrier in human subjects Peptides 8 1987 261 265 (Pubitemid 17065131)
151. R. Pietrowsky, C. Struben, M. Molle, H.L. Fehm, and J. Born Brain potential changes after intranasal vs. intravenous administration of vasopressin: evidence for a direct nose-brain pathway for peptide effects in humans Biol. Psychiatry 39 1996 332 340 (Pubitemid 26122559)
152. W.A. Banks, M.J. During, and M.L. Niehoff Brain uptake of the glucagon-like peptide-1 antagonist exendin(9-39) after intranasal administration J. Pharmacol. Exp. Ther. 309 2004 469 475 (Pubitemid 38542596)
153. I. Kovalszky, E. Surmacz, L. Scolaro, M. Cassone, R. Ferla, A. Sztodola, J. Olah, M.P. Hatfield, S. Lovas, and L. Otvos Jr. Leptin-based glycopeptide induces weight loss and simultaneously restores fertility in animal models Diabetes Obes. Metab. 12 2010 393 402
154. T.M. Ross, P.M. Martinez, J.C. Renner, R.G. Thorne, L.R. Hanson, and W.H. Frey II Intranasal administration of interferon beta bypasses the blood-brain barrier to target the central nervous system and cervical lymph nodes: a non-invasive treatment strategy for multiple sclerosis J. Neuroimmunol. 151 2004 66 77 (Pubitemid 38624401)
155. N. Nonaka, S.A. Farr, T. Nakamachi, J.E. Morley, M. Nakamura, S. Shioda, and W.A. Banks Intranasal administration of PACAP: uptake by brain and regional brain targeting with cyclodextrins Peptides 36 2012 168 175
156. M.M. Migliore, T.K. Vyas, R.B. Campbell, M.M. Amiji, and B.L. Waszczak Brain delivery of proteins by the intranasal route of administration: a comparison of cationic liposomes versus aqueous solution formulations J. Pharm. Sci. 99 2010 1745 1761
157. R.D. Broadwell, and B.J. Balin Endocytic and exocytic pathways of the neuronal secretory process and trans-synaptic transfer of wheat germ agglutinin-horseradish peroxidase in vivo J. Comp. Neurol. 242 1985 632 650 (Pubitemid 16176081)
158. H. Baker, and R.F. Spencer Transneuronal transport of peroxidase-conjugated wheat germ agglutinin (WGA-HRP) from the olfactory epithelium to the brain of the adult rat Exp. Brain Res. Exp. Hirnforsch. 63 1986 461 473 (Pubitemid 16036221)
159. J. Corning Spinal anaesthesia and local medication of the cord N. Y. Med. J. 42 1885 3
160. Y. Okuda, S. Sakoda, H. Fujimura, S. Nagata, T. Yanagihara, and C.C. Bernard Intrathecal administration of neutralizing antibody against Fas ligand suppresses the progression of experimental autoimmune encephalomyelitis Biochem. Biophys. Res. Commun. 275 2000 164 168 (Pubitemid 30663646)
161. C.M. Cahill, A. Dray, and T.J. Coderre Intrathecal nerve growth factor restores opioid effectiveness in an animal model of neuropathic pain Neuropharmacology 45 2003 543 552 (Pubitemid 36936987)
162. N.C. Bambakidis, M. Petrullis, X. Kui, B. Rothstein, I. Karampelas, Y. Kuang, W.R. Selman, J.C. LaManna, and R.H. Miller Improvement of neurological recovery and stimulation of neural progenitor cell proliferation by intrathecal administration of Sonic hedgehog J. Neurosurg. 116 2012 1114 1120
163. M.B. Papisov, V. Belov, A.J. Fischman, E. Belova, J. Titus, M. Gagne, and C. Gillooly Delivery of proteins to CNS as seen and measured by Positron Emission Tomography Drug Deliv. Transl. Res. 2 2012 9
164. G. Ochs, R.D. Penn, M. York, R. Giess, M. Beck, J. Tonn, J. Haigh, E. Malta, M. Traub, M. Sendtner, and K.V. Toyka A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis Amyotroph. lateral Scler. Other Mot. Neuron Disord. 1 2000 201 206
165. A.D. Dierenfeld, M.F. McEntee, C.A. Vogler, C.H. Vite, A.H. Chen, M. Passage, S. Le, S. Shah, J.K. Jens, E.M. Snella, K.L. Kline, J.D. Parkes, W.A. Ware, L.E. Moran, A.J. Fales-Williams, J.A. Wengert, R.D. Whitley, D.M. Betts, A.M. Boal, E.A. Riedesel, W. Gross, N.M. Ellinwood, and P.I. Dickson Replacing the enzyme alpha-L-iduronidase at birth ameliorates symptoms in the brain and periphery of dogs with mucopolysaccharidosis type I Sci. Transl. Med. 2 2010 60ra89
166. B.R. Vuillemenot, M.L. Katz, J.R. Coates, D. Kennedy, P. Tiger, S. Kanazono, P. Lobel, I. Sohar, S. Xu, R. Cahayag, S. Keve, E. Koren, S. Bunting, L.S. Tsuruda, and C.A. O'Neill Intrathecal tripeptidyl-peptidase 1 reduces lysosomal storage in a canine model of late infantile neuronal ceroid lipofuscinosis Mol. Genet. Metab. 104 2011 325 337
167. Y.B. Sohn, J. Lee, S.Y. Cho, S.J. Kim, A.R. Ko, M.H. Nam, and D.K. Jin Improvement of CNS defects via continuous intrathecal enzyme replacement by osmotic pump in mucopolysaccharidosis type II mice Am. J. Med. Genet. A 161A 2013 1036 1043
168. E. Kakkis, M. McEntee, C. Vogler, S. Le, B. Levy, P. Belichenko, W. Mobley, P. Dickson, S. Hanson, and M. Passage Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I Mol. Genet. Metab. 83 2004 163 174 (Pubitemid 39328075)
169. M.I. Papisov, V.V. Belov, and K.S. Gannon Physiology of the intrathecal bolus: the leptomeningeal route for macromolecule and particle delivery to CNS Mol. Pharm. 10 2013 1522 1532
170. R.G. Soderquist, E.D. Milligan, J.A. Harrison, R.A. Chavez, K.W. Johnson, L.R. Watkins, and M.J. Mahoney PEGylation of interleukin-10 for the mitigation of enhanced pain states J. Biomed. Mater. Res. A 93 2010 1169 1179
171. B.K. Lee, J.S. Kwon, H.J. Kim, S. Yamamoto, and E.K. Lee Solid-phase PEGylation of recombinant interferon alpha-2a for site-specific modification: process performance, characterization, and in vitro bioactivity Bioconjug. Chem. 18 2007 1728 1734 (Pubitemid 350219969)
172. S. Balan, J.W. Choi, A. Godwin, I. Teo, C.M. Laborde, S. Heidelberger, M. Zloh, S. Shaunak, and S. Brocchini Site-specific PEGylation of protein disulfide bonds using a three-carbon bridge Bioconjug. Chem. 18 2007 61 76 (Pubitemid 46145995)
173. S. Brocchini, S. Balan, A. Godwin, J.W. Choi, M. Zloh, and S. Shaunak PEGylation of native disulfide bonds in proteins Nat. Protoc. 1 2006 2241 2252
174. S. Brocchini, A. Godwin, S. Balan, J.W. Choi, M. Zloh, and S. Shaunak Disulfide bridge based PEGylation of proteins Adv. Drug Deliv. Rev. 60 2008 3 12 (Pubitemid 350181163)
175. S. Shaunak, A. Godwin, J.W. Choi, S. Balan, E. Pedone, D. Vijayarangam, S. Heidelberger, I. Teo, M. Zloh, and S. Brocchini Site-specific PEGylation of native disulfide bonds in therapeutic proteins Nat. Chem. Biol. 2 2006 312 313 (Pubitemid 43787211)
176. M. Zloh, S. Shaunak, S. Balan, and S. Brocchini Identification and insertion of 3-carbon bridges in protein disulfide bonds: a computational approach Nat. Protocol. 2 2007 1070 1083 (Pubitemid 46901288)
177. K.F. Geoghegan, and J.G. Stroh Site-directed conjugation of nonpeptide groups to peptides and proteins via periodate oxidation of a 2-amino alcohol. Application to modification at N-terminal serine Bioconjug. Chem. 3 1992 138 146
178. S. Salmaso, S. Bersani, A. Scomparin, F. Mastrotto, R. Scherpfer, G. Tonon, and P. Caliceti Tailored PEG for rh-G-CSF analogue site-specific conjugation Bioconjug. Chem. 20 2009 1179 1185
179. X. Zhang, F. Li, X.W. Lu, and C.F. Liu Protein C-terminal modification through thioacid/azide amidation Bioconjug. Chem. 20 2009 197 200
180. O. Kinstler, G. Molineux, M. Treuheit, D. Ladd, and C. Gegg Mono-N-terminal poly(ethylene glycol)-protein conjugates Adv. Drug Deliv. Rev. 54 2002 477 485 (Pubitemid 34615544)
181. A.K. Kumagai, J.B. Eisenberg, and W.M. Pardridge Absorptive-mediated endocytosis of cationized albumin and a beta-endorphin-cationized albumin chimeric peptide by isolated brain capillaries. Model system of blood-brain barrier transport J. Biol. Chem. 262 1987 15214 15219 (Pubitemid 17160184)
182. W.M. Pardridge, A.K. Kumagai, and J.B. Eisenberg Chimeric peptides as a vehicle for peptide pharmaceutical delivery through the blood-brain barrier Biochem. Biophys. Res. Commun. 146 1987 307 313 (Pubitemid 17102989)
183. D. Triguero, J.B. Buciak, J. Yang, and W.M. Pardridge Blood-brain barrier transport of cationized immunoglobulin G: enhanced delivery compared to native protein Proc. Natl. Acad. Sci. U. S. A. 86 1989 4761 4765 (Pubitemid 19164629)
184. J.F. Poduslo, and G.L. Curran Polyamine modification increases the permeability of proteins at the blood-nerve and blood-brain barriers J. Neurochem. 66 1996 1599 1609 (Pubitemid 26093697)
185. J.F. Poduslo, and G.L. Curran Permeability at the blood-brain and blood-nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF Brain Res. 36 1996 280 286 (Pubitemid 26095587)
186. T.M. Wengenack, G.L. Curran, and J.F. Poduslo Postischemic, systemic administration of polyamine-modified superoxide dismutase reduces hippocampal CA1 neurodegeneration in rat global cerebral ischemia Brain Res. 754 1997 46 54 (Pubitemid 27170250)
187. J.F. Poduslo, G.L. Curran, J.A. Peterson, D.J. McCormick, A.H. Fauq, M.A. Khan, and T.M. Wengenack Design and chemical synthesis of a magnetic resonance contrast agent with enhanced in vitro binding, high blood-brain barrier permeability, and in vivo targeting to Alzheimer's disease amyloid plaques Biochemistry 43 2004 6064 6075 (Pubitemid 38669474)
188. J.F. Poduslo, and G.L. Curran Increased permeability of superoxide dismutase at the blood-nerve and blood-brain barriers with retained enzymatic activity after covalent modification with the naturally occurring polyamine, putrescine J. Neurochem. 67 1996 734 741 (Pubitemid 26255671)
189. S.G. Adler, H. Wang, H.J. Ward, A.H. Cohen, and W.A. Border Electrical charge. Its role in the pathogenesis and prevention of experimental membranous nephropathy in the rabbit J. Clin. Investig. 71 1983 487 499 (Pubitemid 13160794)
190. J.T. Huang, M. Mannik, and J. Gleisner In situ formation of immune complexes in the choroid plexus of rats by sequential injection of a cationized antigen and unaltered antibodies J. Neuropathol. Exp. Neurol. 43 1984 489 499 (Pubitemid 14027584)
191. H.J. Ward, A.H. Cohen, and W.A. Border In situ formation of subepithelial immune complexes in the rabbit glomerulus: requirement of a cationic antigen Nephron 36 1984 257 264 (Pubitemid 14192568)
192. J.E. Hardebo, and J. Kahrstrom Endothelial negative surface charge areas and blood-brain barrier function Acta Physiol. Scand. 125 1985 495 499 (Pubitemid 16223776)
193. Z. Nagy, H. Peters, and I. Huttner Charge-related alterations of the cerebral endothelium Lab. Investig. 49 1983 662 671 (Pubitemid 14220332)
194. V.M. Vehaskari, C.T. Chang, J.K. Stevens, and A.M. Robson The effects of polycations on vascular permeability in the rat. A proposed role for charge sites J. Clin. Investig. 73 1984 1053 1061 (Pubitemid 14132835)
195. E. Vives, P. Brodin, and B. Lebleu A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus J. Biol. Chem. 272 1997 16010 16017 (Pubitemid 27265584)
196. G. Drin, M. Mazel, P. Clair, D. Mathieu, M. Kaczorek, and J. Temsamani Physico-chemical requirements for cellular uptake of pAntp peptide. Role of lipid-binding affinity Eur. J. Biochem. 268 2001 1304 1314 (Pubitemid 32231883)
197. P.A. Wender, D.J. Mitchell, K. Pattabiraman, E.T. Pelkey, L. Steinman, and J.B. Rothbard The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters Proc. Natl. Acad. Sci. U. S. A. 97 2000 13003 13008
198. M. Lindgren, M. Hallbrink, A. Prochiantz, and U. Langel Cell-penetrating peptides Trends Pharmacol. Sci. 21 2000 99 103 (Pubitemid 30114324)
199. F. Herve, N. Ghinea, and J.M. Scherrmann CNS delivery via adsorptive transcytosis AAPS J. 10 2008 455 472
200. S.R. Schwarze, A. Ho, A. Vocero-Akbani, and S.F. Dowdy In vivo protein transduction: delivery of a biologically active protein into the mouse Science 285 1999 1569 1572 (Pubitemid 29420581)
201. G.P. Dietz, P.C. Valbuena, B. Dietz, K. Meuer, P. Mueller, J.H. Weishaupt, and M. Bahr Application of a blood-brain-barrier-penetrating form of GDNF in a mouse model for Parkinson's disease Brain Res. 1082 2006 61 66
202. G. Cao, W. Pei, H. Ge, Q. Liang, Y. Luo, F.R. Sharp, A. Lu, R. Ran, S.H. Graham, and J. Chen In vivo delivery of a Bcl-xL fusion protein containing the TAT protein transduction domain protects against ischemic brain injury and neuronal apoptosis J. Neurosci. 22 2002 5423 5431 (Pubitemid 35386464)
203. E. Kilic, G.P. Dietz, D.M. Hermann, and M. Bahr Intravenous TAT-Bcl-Xl is protective after middle cerebral artery occlusion in mice Ann. Neurol. 52 2002 617 622 (Pubitemid 35246865)
204. C. Zhang, Z. Su, B. Zhao, Q. Qu, Y. Tan, L. Cai, and X. Li Tat-modified leptin is more accessible to hypothalamus through brain-blood barrier with a significant inhibition of body-weight gain in high-fat-diet fed mice Exp. Clin. Endocrinol. Diabetes 118 2010 31 37
205. B. Cai, Y. Lin, X.H. Xue, L. Fang, N. Wang, and Z.Y. Wu TAT-mediated delivery of neuroglobin protects against focal cerebral ischemia in mice Exp. Neurol. 227 2011 224 231
206. L. Xiang, R. Zhou, A. Fu, X. Xu, Y. Huang, and C. Hu Targeted delivery of large fusion protein into hippocampal neurons by systemic administration J. Drug Target. 19 2012 632 636
207. A. Fu, Y. Wang, L. Zhan, and R. Zhou Targeted delivery of proteins into the central nervous system mediated by rabies virus glycoprotein-derived peptide Pharm. Res. 29 2011 1562 1569
208. G. Sarkar, G.L. Curran, E. Mahlum, T. Decklever, T.M. Wengenack, A. Blahnik, B. Hoesley, V.J. Lowe, J.F. Poduslo, and R.B. Jenkins A carrier for non-covalent delivery of functional beta-galactosidase and antibodies against amyloid plaques and IgM to the brain PLoS ONE 6 1991 e28881
209. V.P. Chekhonin, A.V. Kabanov, Y.A. Zhirkov, and G.V. Morozov Fatty acid acylated Fab-fragments of antibodies to neurospecific proteins as carriers for neuroleptic targeted delivery in brain FEBS Lett. 287 1991 149 152
210. J. Chopineau, S. Robert, L. Fenart, R. Cecchelli, B. Lagoutte, S. Paitier, M.P. Dehouck, and D. Domurado Monoacylation of ribonuclease A enables its transport across an in vitro model of the blood-brain barrier J. Control. Release 56 1998 231 237 (Pubitemid 28511143)
211. V.I. Slepnev, L. Phalente, H. Labrousse, N.S. Melik-Nubarov, V. Mayau, B. Goud, G. Buttin, and A.V. Kabanov Fatty acid acylated peroxidase as a model for the study of interactions of hydrophobically-modified proteins with mammalian cells Bioconjug. Chem. 6 1995 608 615
212. E.V. Batrakova, S.V. Vinogradov, S.M. Robinson, M.L. Niehoff, W.A. Banks, and A.V. Kabanov Polypeptide point modifications with fatty acid and amphiphilic block copolymers for enhanced brain delivery Bioconjug. Chem. 16 2005 793 802 (Pubitemid 41026165)
213. L. Yuan, J. Wang, and W.C. Shen Lipidization of human interferon-alpha: a new approach toward improving the delivery of protein drugs J. Control. Release 129 2008 11 17
214. M.D. Resh Trafficking and signaling by fatty-acylated and prenylated proteins Nat. Chem. Biol. 2 2006 584 590 (Pubitemid 44610342)
215. J. Edmond Essential polyunsaturated fatty acids and the barrier to the brain: the components of a model for transport J. Mol. Neurosci. 16 2001 181 193 (discussion 215-121) (Pubitemid 32664778)
216. J. Edmond, T.A. Higa, R.A. Korsak, E.A. Bergner, and W.N. Lee Fatty acid transport and utilization for the developing brain J. Neurochem. 70 1998 1227 1234 (Pubitemid 28113658)
217. C.Y. Chen, M. Fujimiya, A. Asakawa, F.Y. Chang, J.T. Cheng, S.D. Lee, and A. Inui At the cutting edge: ghrelin gene products in food intake and gut motility Neuroendocrinology 89 2009 9 17
218. M. Kojima, H. Hosoda, Y. Date, M. Nakazato, H. Matsuo, and K. Kangawa Ghrelin is a growth-hormone-releasing acylated peptide from stomach Nature 402 1999 656 660 (Pubitemid 129516334)
219. M.A. Bednarek, S.D. Feighner, S.S. Pong, K.K. McKee, D.L. Hreniuk, M.V. Silva, V.A. Warren, A.D. Howard, L.H. Van Der Ploeg, and J.V. Heck Structure-function studies on the new growth hormone-releasing peptide, ghrelin: minimal sequence of ghrelin necessary for activation of growth hormone secretagogue receptor 1a J. Med. Chem. 43 2000 4370 4376 (Pubitemid 32046862)
220. W.A. Banks, M. Tschop, S.M. Robinson, and M.L. Heiman Extent and direction of ghrelin transport across the blood-brain barrier is determined by its unique primary structure J. Pharmacol. Exp. Ther. 302 2002 822 827 (Pubitemid 34787253)
221. J.J. Holst The physiology of glucagon-like peptide 1 Physiol. Rev. 87 2007 1409 1439 (Pubitemid 350041474)
222. A. Garber, R.R. Henry, R. Ratner, P. Hale, C.T. Chang, and B. Bode Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes Diabetes Obes. Metab. 13 2011 348 356
223. S.E. Kanoski, L.E. Rupprecht, S.M. Fortin, B.C. De Jonghe, and M.R. Hayes The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide Neuropharmacology 62 2012 1916 1927
224. M.J. Jespersen, F.K. Knop, and M. Christensen GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations Expert Opin. Drug Metab. Toxicol. 9 2013 17 29
225. X. Yi, and A.V. Kabanov Brain delivery of proteins via their fatty acid and block copolymer modifications J. Drug Target. 21 2013 940 955
226. A. Tsuji Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems NeuroRx 2 2005 54 62 (Pubitemid 40128026)
227. I. Brasnjevic, H.W. Steinbusch, C. Schmitz, and P. Martinez-Martinez Delivery of peptide and protein drugs over the blood-brain barrier Prog. Neurobiol. 87 2009 212 251
228. I. van Rooy, S. Cakir-Tascioglu, P.O. Couraud, I.A. Romero, B. Weksler, G. Storm, W.E. Hennink, R.M. Schiffelers, and E. Mastrobattista Identification of peptide ligands for targeting to the blood-brain barrier Pharm Res 27 2010 673 682
229. W.M. Pardridge, J.L. Buciak, and P.M. Friden Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo J. Pharmacol. Exp. Ther. 259 1991 66 70
230. W.M. Pardridge Drug and gene targeting to the brain via blood-brain barrier receptor-mediated transport systems Int. Congr. Ser. 1277 2005 49 59
231. D. Wu, B.W. Song, H.V. Vinters, and W.M. Pardridge Pharmacokinetics and brain uptake of biotinylated basic fibroblast growth factor conjugated to a blood-brain barrier drug delivery system J. Drug Target. 10 2002 239 245 (Pubitemid 34467293)
232. B.W. Song, H.V. Vinters, D. Wu, and W.M. Pardridge Enhanced neuroprotective effects of basic fibroblast growth factor in regional brain ischemia after conjugation to a blood-brain barrier delivery vector J. Pharmacol. Exp. Ther. 301 2002 605 610 (Pubitemid 34429974)
233. A. Kurihara, Y. Deguchi, and W.M. Pardridge Epidermal growth factor radiopharmaceuticals: 111In chelation, conjugation to a blood-brain barrier delivery vector via a biotin-polyethylene linker, pharmacokinetics, and in vivo imaging of experimental brain tumors Bioconjug. Chem. 10 1999 502 511 (Pubitemid 29243335)
234. W.M. Pardridge, Y.S. Kang, and J.L. Buciak Transport of human recombinant brain-derived neurotrophic factor (BDNF) through the rat blood-brain barrier in vivo using vector-mediated peptide drug delivery Pharm. Res. 11 1994 738 746 (Pubitemid 24171772)
235. U. Bickel, T. Yoshikawa, E.M. Landaw, K.F. Faull, and W.M. Pardridge Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery Proc. Natl. Acad. Sci. U. S. A. 90 1993 2618 2622 (Pubitemid 23113467)
236. Q.H. Zhou, R.J. Boado, J.Z. Lu, E.K. Hui, and W.M. Pardridge Re-engineering erythropoietin as an IgG fusion protein that penetrates the blood-brain barrier in the mouse Mol. Pharm. 7 2010 2148 2155
237. A. Fu, E.K. Hui, J.Z. Lu, R.J. Boado, and W.M. Pardridge Neuroprotection in stroke in the mouse with intravenous erythropoietin-Trojan horse fusion protein Brain Res. 1369 2011 203 207
238. Q.H. Zhou, E.K. Hui, J.Z. Lu, R.J. Boado, and W.M. Pardridge Brain penetrating IgG-erythropoietin fusion protein is neuroprotective following intravenous treatment in Parkinson's disease in the mouse Brain Res. 1382 2011 315 320
239. R.J. Boado, E.K. Hui, J.Z. Lu, Q.H. Zhou, and W.M. Pardridge Reversal of lysosomal storage in brain of adult MPS-I mice with intravenous Trojan horse-iduronidase fusion protein Mol. Pharm. 8 2011 1342 1350
240. Q.H. Zhou, A. Fu, R.J. Boado, E.K. Hui, J.Z. Lu, and W.M. Pardridge Receptor-mediated abeta amyloid antibody targeting to Alzheimer's disease mouse brain Mol. Pharm. 8 2011 280 285
241. Q.H. Zhou, J.Z. Lu, E.K. Hui, R.J. Boado, and W.M. Pardridge Delivery of a peptide radiopharmaceutical to brain with an IgG-avidin fusion protein Bioconjug. Chem. 22 2011 1611 1618
242. Q.H. Zhou, R.J. Boado, J.Z. Lu, E.K. Hui, W.M. Pardridge. Monoclonal antibody-glial-derived neurotrophic factor fusion protein penetrates the blood-brain barrier in the mouse, Drug Metab. Dispos. 38 566-572.
243. A. Fu, Q.H. Zhou, E.K. Hui, J.Z. Lu, R.J. Boado, W.M. Pardridge. Intravenous treatment of experimental Parkinson's disease in the mouse with an IgG-GDNF fusion protein that penetrates the blood-brain barrier. Brain Res. 1352 208-213.
244. Q.H. Zhou, R.J. Boado, E.K. Hui, J.Z. Lu, W.M. Pardridge. Chronic dosing of mice with a transferrin receptor monoclonal antibody-glial-derived neurotrophic factor fusion protein. Drug Metab. Dispos. 39 1149-1154.
245. Q.H. Zhou, R.J. Boado, E.K. Hui, J.Z. Lu, and W.M. Pardridge Brain-penetrating tumor necrosis factor decoy receptor in the mouse Drug Metab. Dispos. 39 2011 71 76
246. R.J. Boado, Q.H. Zhou, J.Z. Lu, E.K. Hui, and W.M. Pardridge Pharmacokinetics and brain uptake of a genetically engineered bifunctional fusion antibody targeting the mouse transferrin receptor Mol. Pharm. 7 2010 237 244
247. L. Xu, W.H. Tang, C.C. Huang, W. Alexander, L.M. Xiang, K.F. Pirollo, A. Rait, and E.H. Chang Systemic p53 gene therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFv Mol. Med. 7 2001 723 734 (Pubitemid 33070986)
248. L.X. Zhao, B. Yan, L. Xu, S.W. Jiang, Y.Y. Zhang, Z.X. Yang, X.W. Zhou, and P.T. Huang Expression, purification and activity analysis of anti-human transferrin receptor scFv Chin. J. Biotechnol. Sheng wu gong cheng xue bao 22 2006 488 491
249. T. Moos, and E.H. Morgan Restricted transport of anti-transferrin receptor antibody (OX26) through the blood-brain barrier in the rat J. Neurochem. 79 2001 119 129 (Pubitemid 32946649)
250. S. Gosk, C. Vermehren, G. Storm, and T. Moos Targeting anti-transferrin receptor antibody (OX26) and OX26-conjugated liposomes to brain capillary endothelial cells using in situ perfusion J. Cereb. Blood Flow Metab. 24 2004 1193 1204 (Pubitemid 39482480)
251. N. Bien-Ly, Y.J. Yu, D. Bumbaca, J. Elstrott, C.A. Boswell, Y. Zhang, W. Luk, Y. Lu, M.S. Dennis, R.M. Weimer, I. Chung, and R.J. Watts Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants J. Exp. Med. 211 2014 233 244
252. J.A. Couch, Y.J. Yu, Y. Zhang, J.M. Tarrant, R.N. Fuji, W.J. Meilandt, H. Solanoy, R.K. Tong, K. Hoyte, W. Luk, Y. Lu, K. Gadkar, S. Prabhu, B.A. Ordonia, Q. Nguyen, Y. Lin, Z. Lin, M. Balazs, K. Scearce-Levie, J.A. Ernst, M.S. Dennis, and R.J. Watts Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier Sci. Transl. Med. 5 2013 183ra157 (181-112)
253. M.J. Coloma, H.J. Lee, A. Kurihara, E.M. Landaw, R.J. Boado, S.L. Morrison, and W.M. Pardridge Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor Pharm. Res. 17 2000 266 274 (Pubitemid 30225129)
254. R.J. Boado, Y. Zhang, Y. Zhang, Y. Wang, and W.M. Pardridge GDNF fusion protein for targeted-drug delivery across the human blood-brain barrier Biotech. Bioeng. 100 2008 387 396 (Pubitemid 351758180)
255. R.J. Boado, and W.M. Pardridge Comparison of blood-brain barrier transport of glial-derived neurotrophic factor (GDNF) and an IgG-GDNF fusion protein in the rhesus monkey Drug Metab. Dispos. 37 2009 2299 2304
256. R.J. Boado, E.K. Hui, J.Z. Lu, and W.M. Pardridge Drug targeting of erythropoietin across the primate blood-brain barrier with an IgG molecular Trojan horse J. Pharmacol. Exp. Ther. 333 2010 961 969
257. A. Fu, E.K. Hui, J.Z. Lu, R.J. Boado, and W.M. Pardridge Neuroprotection in experimental stroke in the rat with an IgG-erythropoietin fusion protein Brain Res. 1360 2010 193 197
258. R.J. Boado, E.K. Hui, J.Z. Lu, Q.H. Zhou, and W.M. Pardridge Selective targeting of a TNFR decoy receptor pharmaceutical to the primate brain as a receptor-specific IgG fusion protein J. Biotechnol. 146 2010 84 91
259. R.J. Boado, J.Z. Lu, E.K. Hui, and W.M. Pardridge IgG-single chain Fv fusion protein therapeutic for Alzheimer's disease: Expression in CHO cells and pharmacokinetics and brain delivery in the rhesus monkey Biotechnol. Bioeng. 105 2010 627 635
260. P. May, E. Woldt, R.L. Matz, and P. Boucher The LDL receptor-related protein (LRP) family: an old family of proteins with new physiological functions Ann. Med. 39 2007 219 228 (Pubitemid 46676481)
261. A. Saito, S. Pietromonaco, A.K. Loo, and M.G. Farquhar Complete cloning and sequencing of rat gp330/"megalin," a distinctive member of the low density lipoprotein receptor gene family Proc. Natl. Acad. Sci. U. S. A. 91 1994 9725 9729
262. A. Gaultier, X. Wu, N. Le Moan, S. Takimoto, G. Mukandala, K. Akassoglou, W.M. Campana, and S.L. Gonias Low-density lipoprotein receptor-related protein 1 is an essential receptor for myelin phagocytosis J. Cell Sci. 122 2009 1155 1162
263. R. Deane, R.D. Bell, A. Sagare, and B.V. Zlokovic Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease CNS Neurol. Disord. Drug Targets 8 2009 16 30
264. C. Zhang, J. An, D.K. Strickland, and M. Yepes The low-density lipoprotein receptor-related protein 1 mediates tissue-type plasminogen activator-induced microglial activation in the ischemic brain Am. J. Pathol. 174 2009 586 594
265. B.V. Zlokovic, C.L. Martel, E. Matsubara, J.G. McComb, G. Zheng, R.T. McCluskey, B. Frangione, and J. Ghiso Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers Proc. Natl. Acad. Sci. U. S. A. 93 1996 4229 4234
266. R. Deane, Z. Wu, and B.V. Zlokovic RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier Stroke 35 2004 2628 2631 (Pubitemid 39458354)
267. M. Demeule, J. Poirier, J. Jodoin, Y. Bertrand, R.R. Desrosiers, C. Dagenais, T. Nguyen, J. Lanthier, R. Gabathuler, M. Kennard, W.A. Jefferies, D. Karkan, S. Tsai, L. Fenart, R. Cecchelli, and R. Beliveau High transcytosis of melanotransferrin (P97) across the blood-brain barrier J. Neurochem. 83 2002 924 933 (Pubitemid 35316043)
268. M. Yepes, M. Sandkvist, E.G. Moore, T.H. Bugge, D.K. Strickland, and D.A. Lawrence Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein J. Clin. Investig. 112 2003 1533 1540 (Pubitemid 38056279)
269. P. Boucher, M. Gotthardt, W.P. Li, R.G. Anderson, and J. Herz LRP: role in vascular wall integrity and protection from atherosclerosis Science 300 2003 329 332 (Pubitemid 36433724)
270. J. Herz LRP: a bright beacon at the blood-brain barrier J. Clin. Investig. 112 2003 1483 1485 (Pubitemid 38056274)
271. J. Herz, and D.K. Strickland LRP: a multifunctional scavenger and signaling receptor J. Clin. Investig. 108 2001 779 784 (Pubitemid 32880284)
272. M. Demeule, A. Regina, C. Che, J. Poirier, T. Nguyen, R. Gabathuler, J.P. Castaigne, and R. Beliveau Identification and design of peptides as a new drug delivery system for the brain J. Pharmacol. Exp. Ther. 324 2008 1064 1072 (Pubitemid 351397849)
273. Y. Bertrand, J.C. Currie, M. Demeule, A. Regina, C. Che, A. Abulrob, D. Fatehi, H. Sartelet, R. Gabathuler, J.P. Castaigne, D. Stanimirovic, and R. Beliveau Transport characteristics of a novel peptide platform for CNS therapeutics J. Cell Mol. Med. 14 2010 2827 2839
274. M. Demeule, J.C. Currie, Y. Bertrand, C. Che, T. Nguyen, A. Regina, R. Gabathuler, J.P. Castaigne, and R. Beliveau Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2 J. Neurochem. 106 2008 1534 1544
275. R. Gabathuler Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases Neurobiology of disease 37 2010 48 57
276. A. Regina, M. Demeule, C. Che, I. Lavallee, J. Poirier, R. Gabathuler, R. Beliveau, and J.P. Castaigne Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2 Br. J. Pharmacol. 155 2008 185 197
277. J. Drappatz, A. Brenner, E.T. Wong, A. Eichler, D. Schiff, M.D. Groves, T. Mikkelsen, S. Rosenfeld, J. Sarantopoulos, C.A. Meyers, R.M. Fielding, K. Elian, X. Wang, B. Lawrence, M. Shing, S. Kelsey, J.P. Castaigne, and P.Y. Wen Phase I study of GRN1005 in recurrent malignant glioma Clin. Cancer Res. 19 2013 1567 1576
278. R. Kurzrock, N. Gabrail, C. Chandhasin, S. Moulder, C. Smith, A. Brenner, K. Sankhala, A. Mita, K. Elian, D. Bouchard, and J. Sarantopoulos Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors Mol. Cancer Ther. 11 2012 308 316
279. C. Che, G. Yang, C. Thiot, M.C. Lacoste, J.C. Currie, M. Demeule, A. Regina, R. Beliveau, and J.P. Castaigne New Angiopep-modified doxorubicin (ANG1007) and etoposide (ANG1009) chemotherapeutics with increased brain penetration Journal of medicinal chemistry 53 2010 2814 2824
280. W. Ke, K. Shao, R. Huang, L. Han, Y. Liu, J. Li, Y. Kuang, L. Ye, J. Lou, and C. Jiang Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer Biomaterials 30 2009 6976 6985
281. J. Shen, C. Zhan, C. Xie, Q. Meng, B. Gu, C. Li, Y. Zhang, and W. Lu Poly(ethylene glycol)-block-poly(d, l-lactide acid) micelles anchored with angiopep-2 for brain-targeting delivery J. Drug Target 2011
282. K. Shao, R. Huang, J. Li, L. Han, L. Ye, J. Lou, and C. Jiang Angiopep-2 modified PE-PEG based polymeric micelles for amphotericin B delivery targeted to the brain J. Control. Release 147 2010 118 126
283. H. Xin, X. Jiang, J. Gu, X. Sha, L. Chen, K. Law, Y. Chen, X. Wang, Y. Jiang, and X. Fang Angiopep-conjugated poly(ethylene glycol)-co-poly(epsilon- caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma Biomaterials 32 2011 4293 4305
284. H. Gao, S. Zhang, S. Cao, Z. Yang, Z. Pang, and X. Jiang Angiopep-2 and Activatable Cell-Penetrating Peptide Dual-Functionalized Nanoparticles for Systemic Glioma-Targeting Delivery Molecular pharmaceutics 2014 (in press)
285. J. Ren, S. Shen, D. Wang, Z. Xi, L. Guo, Z. Pang, Y. Qian, X. Sun, and X. Jiang The targeted delivery of anticancer drugs to brain glioma by PEGylated oxidized multi-walled carbon nanotubes modified with angiopep-2 Biomaterials 33 2012 3324 3333
286. X. Sun, Z. Pang, H. Ye, B. Qiu, L. Guo, J. Li, J. Ren, Y. Qian, Q. Zhang, J. Chen, and X. Jiang Co-delivery of pEGFP-hTRAIL and paclitaxel to brain glioma mediated by an angiopep-conjugated liposome Biomaterials 33 2012 916 924
287. J.E. Lachowicz, M. Demeule, C. Ché, S. Tripathy, J-C. Currie, A. Régina, T. Nguyen, S. Lord-Dufour, and J-P. Castaigne ANG4043: a new brain-penetrant peptide-mAb conjugate that reduces tumor growth in a HER2-positive orthotopic tumor model AACR Annual Meeting April 2013 2013
288. J.E. Lachowicz, M. Demeule, C. Ché, S. Tripathy, S. Jarvis, J-C. Currie, A. Régina, T. Nguyen, and J-P. Castaigne Design of new Angiopep-2-anti-EGFR and Angiopep-2-anti-HER2 derivatives with increased blood-brain barrier permeability for treatment of brain tumors Society of Neuro-Oncology (SNO) Annual Meeting November 2012 2012
289. M. Demeule, N. Beaudet, A. Regina, E. Besserer-Offroy, A. Murza, P. Tetreault, K. Belleville, C. Che, A. Larocque, C. Thiot, R. Beliveau, J.M. Longpre, E. Marsault, R. Leduc, J.E. Lachowicz, S.L. Gonias, J.P. Castaigne, and P. Sarret Conjugation of a brain-penetrant peptide with neurotensin provides antinociceptive properties J. Clin. Investig. 124 2014 1199 1213
290. A. Bockenhoff, S. Cramer, P. Wolte, S. Knieling, C. Wohlenberg, V. Gieselmann, H.J. Galla, and U. Matzner Comparison of five Peptide vectors for improved brain delivery of the lysosomal enzyme arylsulfatase a J. Neurosci. 34 2014 3122 3129
291. J.P. Brown, K. Nishiyama, I. Hellstrom, and K.E. Hellstrom Structural characterization of human melanoma-associated antigen p97 with monoclonal antibodies J. Immunol. 127 1981 539 546 (Pubitemid 11054661)
292. D.R. Richardson, and E.H. Morgan The transferrin homologue, melanotransferrin (p97), is rapidly catabolized by the liver of the rat and does not effectively donate iron to the brain Biochim. Biophys. Acta 1690 2004 124 133 (Pubitemid 39299190)
293. I. Moroo, M. Ujiie, B.L. Walker, J.W. Tiong, T.Z. Vitalis, D. Karkan, R. Gabathuler, A.R. Moise, and W.A. Jefferies Identification of a novel route of iron transcytosis across the mammalian blood-brain barrier Microcirculation 10 2003 457 462 (Pubitemid 39004271)
294. Y. Tang, T. Han, M. Everts, Z.B. Zhu, G.Y. Gillespie, D.T. Curiel, and H. Wu Directing adenovirus across the blood-brain barrier via melanotransferrin (P97) transcytosis pathway in an in vitro model Gene Ther. 14 2007 523 532 (Pubitemid 46390925)
295. A.G.R. Gabathuler, M. Kennard, Q. Chen, and S. Tsai et al. Development of a potenial vector Neuro Tans to deliver drugs across the blood-brain barrier Int. Congr. Ser. 1277 2005 171 184 (Pubitemid 43693327)
296. D. Karkan, C. Pfeifer, T.Z. Vitalis, G. Arthur, M. Ujiie, Q. Chen, S. Tsai, G. Koliatis, R. Gabathuler, and W.A. Jefferies A unique carrier for delivery of therapeutic compounds beyond the blood-brain barrier PLoS ONE 3 2008 e2469
297. A.G. de Boer, and P.J. Gaillard Drug targeting to the brain Annu. Rev. Pharmacol. Toxicol. 47 2007 323 355
298. I. Warshawsky, G. Bu, and A.L. Schwartz Identification of domains on the 39-kDa protein that inhibit the binding of ligands to the low density lipoprotein receptor-related protein J. Biol. Chem. 268 1993 22046 22054 (Pubitemid 23320714)
299. I. Warshawsky, G. Bu, and A.L. Schwartz 39-kD protein inhibits tissue-type plasminogen activator clearance in vivo J. Clin. Investig. 92 1993 937 944 (Pubitemid 23262417)
300. W. Pan, A.J. Kastin, T.C. Zankel, P. van Kerkhof, T. Terasaki, and G. Bu Efficient transfer of receptor-associated protein (RAP) across the blood-brain barrier J. Cell Sci. 117 2004 5071 5078 (Pubitemid 39517522)
301. W.S. Prince, L.M. McCormick, D.J. Wendt, P.A. Fitzpatrick, K.L. Schwartz, A.I. Aguilera, V. Koppaka, T.M. Christianson, M.C. Vellard, N. Pavloff, J.F. Lemontt, M. Qin, C.M. Starr, G. Bu, and T.C. Zankel Lipoprotein receptor binding, cellular uptake, and lysosomal delivery of fusions between the receptor-associated protein (RAP) and alpha-L-iduronidase or acid alpha-glucosidase J. Biol. Chem. 279 2004 35037 35046 (Pubitemid 39318140)
302. A. Abuchowski, J.R. McCoy, N.C. Palczuk, T. van Es, and F.F. Davis Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase J. Biol. Chem. 252 1977 3582 3586 (Pubitemid 8116088)
303. A. Abuchowski, T. van Es, N.C. Palczuk, and F.F. Davis Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol J. Biol. Chem. 252 1977 3578 3581 (Pubitemid 8116087)
304. D.S. Pisal, M.P. Kosloski, and S.V. Balu-Iyer Delivery of therapeutic proteins J. Pharm. Sci. 99 2010 2557 2575
305. A.P. Chapman PEGylated antibodies and antibody fragments for improved therapy: a review Adv. Drug Deliv. Rev. 54 2002 531 545 (Pubitemid 34615547)
306. K.D. Hinds, and S.W. Kim Effects of PEG conjugation on insulin properties Adv. Drug Deliv. Rev. 54 2002 505 530 (Pubitemid 34615546)
307. M.J. Roberts, M.D. Bentley, and J.M. Harris Chemistry for peptide and protein PEGylation Adv. Drug Deliv. Rev. 54 2002 459 476 (Pubitemid 34615543)
308. H. Sato Enzymatic procedure for site-specific pegylation of proteins Adv. Drug Deliv. Rev. 54 2002 487 504 (Pubitemid 34615545)
309. V.P. Torchilin PEG-based micelles as carriers of contrast agents for different imaging modalities Adv. Drug Deliv. Rev. 54 2002 235 252 (Pubitemid 34230444)
310. F.M. Veronese, P. Caliceti, O. Schiavon, and M. Sergi Polyethylene glycol-superoxide dismutase, a conjugate in search of exploitation Adv. Drug Deliv. Rev. 54 2002 587 606 (Pubitemid 34615549)
311. Y.S. Wang, S. Youngster, M. Grace, J. Bausch, R. Bordens, and D.F. Wyss Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications Adv. Drug Deliv. Rev. 54 2002 547 570 (Pubitemid 34618512)
312. J.M. Harris, and R.B. Chess Effect of pegylation on pharmaceuticals Nat. Rev. 2 2003 214 221 (Pubitemid 37361666)
313. P. Bailon, and C.Y. Won PEG-modified biopharmaceuticals Expert Opin. Drug Deliv. 6 2009 1 16
314. E. Bianchi, P.E. Carrington, P. Ingallinella, M. Finotto, A. Santoprete, A. Petrov, G. Eiermann, J. Kosinski, D.J. Marsh, A. Pocai, R. SinhaRoy, and A. Pessi A PEGylated analog of the gut hormone oxyntomodulin with long-lasting antihyperglycemic, insulinotropic and anorexigenic activity Bioorg. Med. Chem. 21 2013 7064 7073
315. M.P. Lejeune, C.J. Hukshorn, W.H. Saris, and M.S. Westerterp-Plantenga Effect of dietary restraint during and following pegylated recombinant leptin (PEG-OB) treatment of overweight men Int. J. Obes. Relat. Metab. Disord. 27 2003 1494 1499 (Pubitemid 38019162)
316. C.J. Hukshorn, F.M. van Dielen, W.A. Buurman, M.S. Westerterp-Plantenga, L.A. Campfield, and W.H. Saris The effect of pegylated recombinant human leptin (PEG-OB) on weight loss and inflammatory status in obese subjects Int. J. Obes. Relat. Metab. Disord. 26 2002 504 509 (Pubitemid 34407263)
317. K.M. Lo, J. Zhang, Y. Sun, B. Morelli, Y. Lan, S. Lauder, B. Brunkhorst, G. Webster, S. Hallakou-Bozec, L. Doare, and S.D. Gillies Engineering a pharmacologically superior form of leptin for the treatment of obesity Protein Eng. Des. Sel. 18 2005 1 10 (Pubitemid 40516986)
318. W.M. Pardridge, D. Wu, and T. Sakane Combined use of carboxyl-directed protein pegylation and vector-mediated blood-brain barrier drug delivery system optimizes brain uptake of brain-derived neurotrophic factor following intravenous administration Pharm. Res. 15 1998 576 582 (Pubitemid 28214951)
319. K. Yoshida, G.F. Burton, J.S. McKinney, H. Young, and E.F. Ellis Brain and tissue distribution of polyethylene glycol-conjugated superoxide dismutase in rats Stroke 23 1992 865 869
320. J. Hardwicke, R. Moseley, P. Stephens, K. Harding, R. Duncan, and D.W. Thomas Bioresponsive dextrin-rhEGF conjugates: in vitro evaluation in models relevant to its proposed use as a treatment for chronic wounds Mol. Pharm. 7 2010 699 707
321. E.L. Ferguson, and R. Duncan Dextrin-phospholipase A2: synthesis and evaluation as a bioresponsive anticancer conjugate Biomacromolecules 10 2009 1358 1364
322. J. Hardwicke, E.L. Ferguson, R. Moseley, P. Stephens, D.W. Thomas, and R. Duncan Dextrin-rhEGF conjugates as bioresponsive nanomedicines for wound repair J. Control. Release 130 2008 275 283
323. R. Duncan, H.R. Gilbert, R.J. Carbajo, and M.J. Vicent Polymer masked-unmasked protein therapy. 1. Bioresponsive dextrin-trypsin and -melanocyte stimulating hormone conjugates designed for alpha-amylase activation Biomacromolecules 9 2008 1146 1154 (Pubitemid 351639566)
324. P.K. Oh EJ, K.S. Kim, J. Kim, J.A. Yang, J.H. Kong, M.Y. Lee, A.S. Hoffman, and S.K. Hahn Target specific and long-acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives J. Control. Release 141 2010 2 12
325. J. Kopecek, and P. Kopeckova HPMA copolymers: origins, early developments, present, and future Adv. Drug Deliv. Rev. 62 2009 122 149
326. A.V. Kabanov, V.P. Chekhonin, V. Alakhov, E.V. Batrakova, A.S. Lebedev, N.S. Melik-Nubarov, S.A. Arzhakov, A.V. Levashov, G.V. Morozov, and E.S. Severin et al. The neuroleptic activity of haloperidol increases after its solubilization in surfactant micelles. Micelles as microcontainers for drug targeting FEBS Lett. 258 1989 343 345 (Pubitemid 20001084)
327. E.V. Batrakova, D.W. Miller, S. Li, V.Y. Alakhov, A.V. Kabanov, and W.F. Elmquist Pluronic P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies J. Pharmacol. Exp. Ther. 296 2001 551 557 (Pubitemid 32112485)
328. E.V. Batrakova, H.Y. Han, D.W. Miller, and A.V. Kabanov Effects of pluronic P85 unimers and micelles on drug permeability in polarized BBMEC and Caco-2 cells Pharm. Res. 15 1998 1525 1532 (Pubitemid 28465737)
329. E.V. Batrakova, S. Li, D.W. Miller, and A.V. Kabanov Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers Pharm. Res. 16 1999 1366 1372 (Pubitemid 29449372)
330. S.N. Nametkin, L.D. AK, A.V. Kabanov, and A.V. Levashov Modulation of membrane activity of an enzyme in reversed micelle system with a change of media pH (using alkaline phosphatase as an example) Bioorg. Khim. 18 1992 777 783
331. E.V. Batrakova, S. Li, V.Y. Alakhov, D.W. Miller, and A.V. Kabanov Optimal structure requirements for pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells J. Pharmacol. Exp. Ther. 304 2003 845 854 (Pubitemid 36152365)
332. G. Sahay, V. Gautam, R. Luxenhofer, and A.V. Kabanov The utilization of pathogen-like cellular trafficking by single chain block copolymer Biomaterials 31 2009 1757 1764
333. G. Sahay, E.V. Batrakova, and A.V. Kabanov Different internalization pathways of polymeric micelles and unimers and their effects on vesicular transport Bioconjug. Chem. 19 2008 2023 2029
334. G. Sahay, V. Gautam, R. Luxenhofer, and A.V. Kabanov The utilization of pathogen-like cellular trafficking by single chain block copolymer Biomaterials 31 2010 1757 1764
335. X. Yi, E. Batrakova, W.A. Banks, S. Vinogradov, and A.V. Kabanov Protein conjugation with amphiphilic block copolymers for enhanced cellular delivery Bioconjug. Chem. 19 2008 1071 1077 (Pubitemid 351748316)
336. X. Yi, M.C. Zimmerman, R. Yang, J. Tong, S. Vinogradov, and A.V. Kabanov Pluronic-modified superoxide dismutase 1 attenuates angiotensin II-induced increase in intracellular superoxide in neurons Free Radic. Biol. Med. 49 2010 548 558
337. X. Yi Protein Modification by Pluronic Block Copolymer for Brain Delivery (Thesis) 2010 University of Nebraska Medical Center
338. T.O. Price, S.A. Farr, X. Yi, S. Vinogradov, E. Batrakova, W.A. Banks, and A.V. Kabanov Transport across the blood-brain barrier of pluronic leptin J. Pharmacol. Exp. Ther. 333 2010 253 263
339. X. Yi, D. Yuan, S.A. Farr, W.A. Banks, C.-D. Poon, and A.V. Kabanov Pluronic modified leptin with increased systemic circulation, brain uptake and efficacy for treatment of obesity J. Control. Release 2014 Jun 2 10.1016/j.jconrel.2014.05.044 pii: S0168-3659(14)00347-2. [Epub ahead of print]
340. B.E. Levin, A.A. Dunn-Meynell, and W.A. Banks Obesity-prone rats have normal blood-brain barrier transport but defective central leptin signaling before obesity onset Am. J. Physiol. 286 2004 R143 R150
341. E. Ravussin, S.R. Smith, J.A. Mitchell, R. Shringarpure, K. Shan, H. Maier, J.E. Koda, and C. Weyer Enhanced weight loss with pramlintide/ metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy Obesity (Silver Spring) 17 2009 1736 1743
342. M. Van Heek, D.S. Compton, C.F. France, R.P. Tedesco, A.B. Fawzi, M.P. Graziano, E.J. Sybertz, C.D. Strader, and H.R. Davis Jr. Diet-induced obese mice develop peripheral, but not central, resistance to leptin J. Clin. Investig. 99 1997 385 390 (Pubitemid 27414794)
343. S. Danson, D. Ferry, V. Alakhov, J. Margison, D. Kerr, D. Jowle, M. Brampton, G. Halbert, and M. Ranson Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer Br. J. Cancer 90 2004 2085 2091 (Pubitemid 38869710)
344. J.W. Valle, A. Armstrong, C. Newman, V. Alakhov, G. Pietrzynski, J. Brewer, S. Campbell, P. Corrie, E.K. Rowinsky, and M. Ranson A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction Investig. New Drugs 2011
345. E.V. Batrakova, Y. Zhang, Y. Li, S. Li, S.V. Vinogradov, Y. Persidsky, V.Y. Alakhov, D.W. Miller, and A.V. Kabanov Effects of pluronic P85 on GLUT1 and MCT1 transporters in the blood-brain barrier Pharm. Res. 21 2004 1993 2000 (Pubitemid 40941218)
346. J. Tong, R. Luxenhofer, X. Yi, R. Jordan, and A.V. Kabanov Protein modification with amphiphilic block copoly(2-oxazoline)s as a new platform for enhanced cellular delivery Mol. Pharm. 7 2010 984 992
347. R. Hoogenboom Poly(2-oxazoline)s: a polymer class with numerous potential applications Angew. Chem. Int. Ed. Engl. 48 2009 7978 7994
348. M. Barz, R. Luxenhofer, R. Zentel, and M.J. Vicent Overcoming the PEG-addiction: well-defined alternatives to PEG, from structure-property relationships to better defined therapeutics Polym. Chem. 2 2009 1900 1918
349. L.Y. Qiu, L. Yan, L. Zhang, Y.M. Jin, and Q.H. Zhao Folate-modified poly(2-ethyl-2-oxazoline) as hydrophilic corona in polymeric micelles for enhanced intracellular doxorubicin delivery Int. J. Pharm. 456 2013 315 324
350. Y. Han, Z. He, A. Schulz, T.K. Bronich, R. Jordan, R. Luxenhofer, and A.V. Kabanov Synergistic combinations of multiple chemotherapeutic agents in high capacity poly(2-oxazoline) micelles Mol. Pharm. 9 2012 2302 2313
351. J. Tong, M.C. Zimmerman, S. Li, X. Yi, R. Luxenhofer, R. Jordan, and A.V. Kabanov Neuronal uptake and intracellular superoxide scavenging of a fullerene (C60)-poly(2-oxazoline)s nanoformulation Biomaterials 32 2011 3654 3665
352. M. Hruby, S.K. Filippov, J. Panek, M. Novakova, H. Mackova, J. Kucka, D. Vetvicka, and K. Ulbrich Polyoxazoline thermoresponsive micelles as radionuclide delivery systems Macromol. Biosci. 10 2010 916 924
353. R. Luxenhofer, A. Schulz, C. Roques, S. Li, T.K. Bronich, E.V. Batrakova, R. Jordan, and A.V. Kabanov Doubly amphiphilic poly(2-oxazoline)s as high-capacity delivery systems for hydrophobic drugs Biomaterials 31 2010 4972 4979
354. G.H. Hsiue, C.H. Wang, C.L. Lo, C.H. Wang, J.P. Li, and J.L. Yang Environmental-sensitive micelles based on poly(2-ethyl-2-oxazoline)-b-poly(L- lactide) diblock copolymer for application in drug delivery Int. J. Pharm. 317 2006 69 75
355. R. Luxenhofer, Y. Han, A. Schulz, J. Tong, Z. He, A.V. Kabanov, and R. Jordan Poly(2-oxazoline)s as polymer therapeutics Macromol. Rapid Commun., n/a-n/a 2012
356. R. Luxenhofer, A. Schulz, C. Roques, S. Li, T.K. Bronich, E.V. Batrakova, R. Jordan, and A.V. Kabanov Doubly amphiphilic poly(2-oxazoline)s as high-capacity delivery systems for hydrophobic drugs Biomaterials 31 2010 4972 4979
357. R. Luxenhofer, G. Sahay, A. Schulz, D. Alakhova, T.K. Bronich, R. Jordan, and A.V. Kabanov Structure-property relationship in cytotoxicity and cell uptake of poly(2-oxazoline) amphiphiles J. Control. Release 153 2011 73 82
358. A. Mero, G. Pasut, L. Dalla Via, M.W. Fijten, U.S. Schubert, R. Hoogenboom, and F.M. Veronese Synthesis and characterization of poly(2-ethyl 2-oxazoline)-conjugates with proteins and drugs: suitable alternatives to PEG-conjugates? J. Control. Release 125 2008 87 95
359. T.X. Viegas, M.D. Bentley, J.M. Harris, Z. Fang, K. Yoon, B. Dizman, R. Weimer, A. Mero, G. Pasut, and F.M. Veronese Polyoxazoline: chemistry, properties, and applications in drug delivery Bioconjug. Chem. 22 2011 976 986
360. J. Tong, R. Luxenhofer, X. Yi, R. Jordan, and A.V. Kabanov Protein modification with amphiphilic block copoly(2-oxazoline)s as a new platform for enhanced cellular delivery Mol. Pharm. 7 2010 984 992
361. J. Tong, X. Yi, R. Luxenhofer, W.A. Banks, R. Jordan, M.C. Zimmerman, and A.V. Kabanov Conjugates of superoxide dismutase 1 with amphiphilic poly(2-oxazoline) block copolymers for enhanced brain delivery: synthesis, characterization and evaluation in vitro and in vivo Mol. Pharm. 10 2013 360 377
362. J.F. Poduslo, and G.L. Curran Increased permeability across the blood-nerve barrier of albumin glycated in vitro and in vivo from patients with diabetic polyneuropathy Proc. Natl. Acad. Sci. U. S. A. 89 1992 2218 2222
363. C. Zhang, Z. Su, B. Zhao, Q. Qu, Y. Tan, L. Cai, and X. Li Tat-modified leptin is more accessible to hypothalamus through brain-blood barrier with a significant inhibition of body-weight gain in high-fat-diet fed mice Exp. Clin. Endocrinol. Diabetes 118 2010 31 37
364. B. Cai, Y. Lin, X.H. Xue, L. Fang, N. Wang, and Z.Y. Wu TAT-mediated delivery of neuroglobin protects against focal cerebral ischemia in mice Exp. Neurol. 227 2011 224 231
365. R.G. Blasberg, J.D. Fenstermacher, and C.S. Patlak Transport of alpha-aminoisobutyric acid across brain capillary and cellular membranes J. Cereb. Blood Flow Metab. 3 1983 8 32 (Pubitemid 13129631)
366. C.S. Patlak, R.G. Blasberg, and J.D. Fenstermacher Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data J. Cereb. Blood Flow Metab. 3 1983 1 7 (Pubitemid 13129630)
367. S.E. Kanoski, S.M. Fortin, M. Arnold, H.J. Grill, and M.R. Hayes Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4 Endocrinology 152 2011 3103 3112
368. T.L. Horvath, S. Diano, P. Sotonyi, M. Heiman, and M. Tschop Minireview: ghrelin and the regulation of energy balance - a hypothalamic perspective Endocrinology 142 2001 4163 4169 (Pubitemid 32907040)
369. C.Y. Chen, A. Asakawa, M. Fujimiya, S.D. Lee, and A. Inui Ghrelin gene products and the regulation of food intake and gut motility Pharm. Rev. 61 2009 430 481
370. A.V. Kabanov, E.V. Batrakova, N.S. Melik-Nubarov, N.A. Fedoseev, T.Y. Dorodnich, V.Y. Alakho, V.P. Chekhonin, I.R. Naaarova, and V.A. Kabanov A new class of drug carriers: micelles of poly (oxyethylene)-poly (oxypropylene) block copolymers as microcontainers for drug targeting from blood in brain J. Control. Release 22 1992 141 158
371. E. Tamariz, A.C. Wan, Y.S. Pek, M. Giordano, G. Hernandez-Padron, A. Varela-Echavarria, I. Velasco, and V.M. Castano Delivery of chemotropic proteins and improvement of dopaminergic neuron outgrowth through a thixotropic hybrid nano-gel J. Mater. Sci. Mater. Med. 22 2011 2097 2109
372. G.R. Dakwar, I.A. Hammad, M. Popov, C. Linder, S. Grinberg, E. Heldman, and D. Stepensky Delivery of proteins to the brain by bolaamphiphilic nano-sized vesicles J. Control. Release 160 2012 315 321
373. S. Wang, T. Jiang, M. Ma, Y. Hu, and J. Zhang Preparation and evaluation of anti-neuroexcitation peptide (ANEP) loaded N-trimethyl chitosan chloride nanoparticles for brain-targeting Int. J. Pharm. 386 2010 249 255
374. W.H. Ren, J. Chang, C.H. Yan, X.M. Qian, L.X. Long, B. He, X.B. Yuan, C.S. Kang, D. Betbeder, J. Sheng, and P.Y. Pu Development of transferrin functionalized poly(ethylene glycol)/poly(lactic acid) amphiphilic block copolymeric micelles as a potential delivery system targeting brain glioma J. Mater. Sci. Mater. Med. 21 2010 2673 2681
375. G. Huile, P. Shuaiqi, Y. Zhi, C. Shijie, C. Chen, J. Xinguo, S. Shun, P. Zhiqing, and H. Yu A cascade targeting strategy for brain neuroglial cells employing nanoparticles modified with angiopep-2 peptide and EGFP-EGF1 protein Biomaterials 32 2011 8669 8675
376. Z. Pang, H. Gao, Y. Yu, J. Chen, L. Guo, J. Ren, Z. Wen, J. Su, and X. Jiang Brain delivery and cellular internalization mechanisms for transferrin conjugated biodegradable polymersomes Int. J. Pharm. 415 2011 284 292
377. C.W. Gan, and S.S. Feng Transferrin-conjugated nanoparticles of poly(lactide)-d-alpha-tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier Biomaterials 31 2010 7748 7757
378. C.C. Visser, S. Stevanovic, L.H. Voorwinden, L. van Bloois, P.J. Gaillard, M. Danhof, D.J. Crommelin, and A.G. de Boer Targeting liposomes with protein drugs to the blood-brain barrier in vitro Eur. J. Pharm. Sci. 25 2005 299 305 (Pubitemid 40725060)
379. Y. Xie, L. Ye, X. Zhang, W. Cui, J. Lou, T. Nagai, and X. Hou Transport of nerve growth factor encapsulated into liposomes across the blood-brain barrier: in vitro and in vivo studies J. Control. Release 105 2005 106 119 (Pubitemid 40805479)
380. I. van Rooy, E. Mastrobattista, G. Storm, W.E. Hennink, and R.M. Schiffelers Comparison of five different targeting ligands to enhance accumulation of liposomes into the brain J. Control. Release 150 2011 30 36
381. C. Roney, P. Kulkarni, V. Arora, P. Antich, F. Bonte, A. Wu, N.N. Mallikarjuana, S. Manohar, H.F. Liang, A.R. Kulkarni, H.W. Sung, M. Sairam, and T.M. Aminabhavi Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease J. Control. Release 108 2005 193 214 (Pubitemid 41608654)
382. Y. Chen, G. Dalwadi, and H.A. Benson Drug delivery across the blood-brain barrier Curr. Drug Deliv. 1 2004 361 376
383. K.B. Kurakhmaeva, I.A. Djindjikhashvili, V.E. Petrov, V.U. Balabanyan, T.A. Voronina, S.S. Trofimov, J. Kreuter, S. Gelperina, D. Begley, and R.N. Alyautdin Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles J. Drug Target. 17 2009 564 574
384. Y.C. Tseng, S. Mozumdar, and L. Huang Lipid-based systemic delivery of siRNA Adv. Drug Deliv. Rev. 61 2009 721 731
385. A.J. Ditto, P.N. Shah, and Y.H. Yun Non-viral gene delivery using nanoparticles Expert Opin. Drug Deliv. 6 2009 1149 1160
386. V.P. Torchilin Recent advances with liposomes as pharmaceutical carriers Nat. Rev. 4 2005 145 160 (Pubitemid 40282557)
387. W.T. Phillips, B.A. Goins, and A. Bao Radioactive liposomes Wiley Interdiscip. Rev. 1 2009 69 83
388. H. Onodera, G. Takada, K. Tada, and R.J. Desnick Microautoradiographic study on the tissue localization of liposome-entrapped or unentrapped 3H-labeled beta-galactosidase injected into rats Tohoku J. Exp. Med. 140 1983 1 13 (Pubitemid 13031473)
389. T.J. Postmes, M. Hukkelhoven, A.E. van den Bogaard, S.G. Halders, and J. Coenegracht Passage through the blood-brain barrier of thyrotropin-releasing hormone encapsulated in liposomes J. Pharm. Pharmacol. 32 1980 722 724 (Pubitemid 11193200)
390. D.B. Stanimirovic, M. Markovic, D.V. Micic, M. Spatz, and B.B. Mrsulja Liposome-entrapped superoxide dismutase reduces ischemia/reperfusion 'oxidative stress' in gerbil brain Neurochem. Res. 19 1994 1473 1478 (Pubitemid 24370062)
391. S. Imaizumi, V. Woolworth, R.A. Fishman, and P.H. Chan Liposome-entrapped superoxide dismutase reduces cerebral infarction in cerebral ischemia in rats Stroke 21 1990 1312 1317 (Pubitemid 20301788)
392. A.M. Michelson, G. Jadot, and K. Puget Treatment of brain trauma with liposomal superoxide dismutase Free Radic. Biol. Med. 4 1988 209 224 (Pubitemid 18073058)
393. P.H. Chan, S. Longar, and R.A. Fishman Protective effects of liposome-entrapped superoxide dismutase on posttraumatic brain edema Ann. Neurol. 21 1987 540 547 (Pubitemid 17081188)
394. M. Fresta, and G. Puglisi Reduction of maturation phenomenon in cerebral ischemia with CDP-choline-loaded liposomes Pharm. Res. 16 1999 1843 1849 (Pubitemid 30040700)
395. S. Chapat, V. Frey, N. Claperon, C. Bouchaud, F. Puisieux, P. Couvreur, P. Rossignol, and J. Delattre Efficiency of liposomal ATP in cerebral ischemia: bioavailability features Brain Res. Bull. 26 1991 339 342
396. M.K. Reddy, and V. Labhasetwar Nanoparticle-mediated delivery of superoxide dismutase to the brain: an effective strategy to reduce ischemia-reperfusion injury FASEB J. 23 2009 1384 1395
397. J. Sinha, N. Das, and M.K. Basu Liposomal antioxidants in combating ischemia-reperfusion injury in rat brain Biomed. Pharmacother. Biomed. Pharmacotherapie 55 2001 264 271 (Pubitemid 32595481)
398. G. Schackert, D. Fan, R. Nayar, and I.J. Fidler Arrest and retention of multilamellar liposomes in the brain of normal mice or mice bearing experimental brain metastases Sel. Cancer Ther. 5 1989 73 79 (Pubitemid 19197885)
399. Z.A. Tokes, A.K. St Peteri, and J.A. Todd Availability of liposome content to the nervous system. Liposomes and the blood-brain barrier Brain Res. 188 1980 282 286 (Pubitemid 10157102)
400. P.R. Hoffmann, J.A. Kench, A. Vondracek, E. Kruk, D.L. Daleke, M. Jordan, P. Marrack, P.M. Henson, and V.A. Fadok Interaction between phosphatidylserine and the phosphatidylserine receptor inhibits immune responses in vivo J. Immunol. 174 2005 1393 1404
401. V.S. Purohit, K. Ramani, R. Sarkar, H.H. Kazazian Jr., and S.V. Balasubramanian Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-O-phospho-l-serine complex J. Biol. Chem. 280 2005 17593 17600 (Pubitemid 41388993)
402. A. Gabizon, and D. Papahadjopoulos Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors Proc. Natl. Acad. Sci. U. S. A. 85 1988 6949 6953
403. H. Chen, L. Tang, Y. Qin, Y. Yin, J. Tang, W. Tang, X. Sun, Z. Zhang, J. Liu, and Q. He Lactoferrin-modified procationic liposomes as a novel drug carrier for brain delivery Eur. J. Pharm. Sci. 40 2010 94 102
404. H. Chen, Y. Qin, Q. Zhang, W. Jiang, L. Tang, J. Liu, and Q. He Lactoferrin modified doxorubicin-loaded procationic liposomes for the treatment of gliomas Eur. J. Pharm. Sci. 44 2011 164 173
405. J. Rip, C.C.M. Appeldoorn, F.M. Manca, R. Dorland, J.M.R. Van Kregten, and P.J. Gaillard Receptor-mediated delivery of drugs across the blood-brain barrier Front. Pharmacol. 2010
406. P.J. Gaillard, C.C. Appeldoorn, J. Rip, R. Dorland, S.M. van der Pol, G. Kooij, H.E. de Vries, and A. Reijerkerk Enhanced brain delivery of liposomal methylprednisolone improved therapeutic efficacy in a model of neuroinflammation J. Control. Release 164 2012 364 369
407. P.J. Gaillard, C.C. Appeldoorn, R. Dorland, J. van Kregten, F. Manca, D.J. Vugts, B. Windhorst, G.A. van Dongen, H.E. de Vries, D. Maussang, and O. van Tellingen Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101) PLoS ONE 9 2014 e82331
408. A. Lindqvist, J. Rip, P.J. Gaillard, S. Bjorkman, and M. Hammarlund-Udenaes Enhanced brain delivery of the opioid peptide DAMGO in glutathione pegylated liposomes: a microdialysis study Mol. Pharm. 10 2013 1533 1541
409. J. Rip, C.C.M. Appeldom, F.M. Manca, R. Dorland, J.M.R. van Kregten, and P.J. Gaillard Receptor-mediated delivery of drugs across the blood-brain barrier Pharmacology and Toxicology of the Blood-brain Barrier: State of the Art, Needs for Future Research and Expected Benefits for the EU, Brussels, Belgium 2010
410. J. Rip, L. Chen, R. Hartman, A. van den Heuvel, A. Reijerkerk, J. van Kregten, B. van der Boom, C. Appeldoorn, M. de Boer, D. Maussang, E.C. de Lange, and P.J. Gaillard Glutathione PEGylated liposomes: pharmacokinetics and delivery of cargo across the blood-brain barrier in rats J. Drug Target. 22 5 2014 Jun 460 467 10.3109/1061186X.2014.888070 Epub 2014 Feb 14
411. M.M. Migliore, T.K. Vyas, R.B. Campbell, M.M. Amiji, and B.L. Waszczak Brain delivery of proteins by the intranasal route of administration: a comparison of cationic liposomes versus aqueous solution formulations J. Pharm. Sci. 99 2010 1745 1761
412. A. Giteau, M.C. Venier-Julienne, A. Aubert-Pouessel, and J.P. Benoit How to achieve sustained and complete protein release from PLGA-based microparticles? Int. J. Pharm. 350 2008 14 26
413. W. Jiang, and S.P. Schwendeman Stabilization of tetanus toxoid encapsulated in PLGA microspheres Mol. Pharm. 5 2008 808 817
414. S.P. Schwendeman Recent advances in the stabilization of proteins encapsulated in injectable PLGA delivery systems Crit. Rev. Ther. Drug Carrier Syst. 19 2002 73 98 (Pubitemid 34521249)
415. C. Carrascosa, I. Torres-Aleman, C. Lopez-Lopez, E. Carro, L. Espejo, S. Torrado, and J.J. Torrado Microspheres containing insulin-like growth factor I for treatment of chronic neurodegeneration Biomaterials 25 2004 707 714 (Pubitemid 37357284)
416. A.M. Fernandez, A.G. de la Vega, and I. Torres-Aleman Insulin-like growth factor I restores motor coordination in a rat model of cerebellar ataxia Proc. Natl. Acad. Sci. U. S. A. 95 1998 1253 1258 (Pubitemid 28124945)
417. J.P. Bertram, M.F. Rauch, K. Chang, and E.B. Lavik Using polymer chemistry to modulate the delivery of neurotrophic factors from degradable microspheres: delivery of BDNF Pharm. Res. 27 2010 82 91
418. A.V. Vergoni, G. Tosi, R. Tacchi, M.A. Vandelli, A. Bertolini, and L. Costantino Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution Nanomedicine 5 2009 369 377
419. L. Costantino, F. Gandolfi, G. Tosi, F. Rivasi, M.A. Vandelli, and F. Forni Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier J. Control. Release 108 2005 84 96 (Pubitemid 41476677)
420. G. Tosi, L. Costantino, F. Rivasi, B. Ruozi, E. Leo, A.V. Vergoni, R. Tacchi, A. Bertolini, M.A. Vandelli, and F. Forni Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123 J. Control. Release 122 2007 1 9 (Pubitemid 47284547)
421. G. Tosi, A.V. Vergoni, B. Ruozi, L. Bondioli, L. Badiali, F. Rivasi, L. Costantino, F. Forni, and M.A. Vandelli Sialic acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: In vivo pharmacological evidence and biodistribution J. Control. Release 145 2010 49 57
422. S.A. Townsend, G.D. Evrony, F.X. Gu, M.P. Schulz, R.H. Brown Jr., and R. Langer Tetanus toxin C fragment-conjugated nanoparticles for targeted drug delivery to neurons Biomaterials 28 2007 5176 5184 (Pubitemid 47488499)
423. F. Xu, W. Lu, H. Wu, L. Fan, X. Gao, and X. Jiang Brain delivery and systemic effect of cationic albumin conjugated PLGA nanoparticles J. Drug Target. 17 2009 423 434
424. Y. Yu, Z. Pang, W. Lu, Q. Yin, H. Gao, and X. Jiang Self-assembled polymersomes conjugated with lactoferrin as novel drug carrier for brain delivery Pharm. Res. 29 2012 83 96
425. K. Hu, Y. Shi, W. Jiang, J. Han, S. Huang, and X. Jiang Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: preparation, characterization and efficacy in Parkinson's disease Int. J. Pharm. 415 2011 273 283
426. J. Kreuter, P. Ramge, V. Petrov, S. Hamm, S.E. Gelperina, B. Engelhardt, R. Alyautdin, H. von Briesen, and D.J. Begley Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles Pharm. Res. 20 2003 409 416 (Pubitemid 36288370)
427. Y. Lin, Y. Pan, Y. Shi, X. Huang, N. Jia, and J.Y. Jiang Delivery of large molecules via poly(butyl cyanoacrylate) nanoparticles into the injured rat brain Nanotechnology 23 2012 165101
428. V. Reukov, V. Maximov, and A. Vertegel Proteins conjugated to poly(butyl cyanoacrylate) nanoparticles as potential neuroprotective agents Biotechnol. Bioeng. 108 2011 243 252
429. P. Calvo, B. Gouritin, H. Chacun, D. Desmaele, J. D'Angelo, J.P. Noel, D. Georgin, E. Fattal, J.P. Andreux, and P. Couvreur Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery Pharm. Res. 18 2001 1157 1166 (Pubitemid 32900402)
430. J.C. Olivier, L. Fenart, R. Chauvet, C. Pariat, R. Cecchelli, and W. Couet Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity Pharm. Res. 16 1999 1836 1842 (Pubitemid 30040699)
431. J. Lode, I. Fichtner, J. Kreuter, A. Berndt, J.E. Diederichs, and R. Reszka Influence of surface-modifying surfactants on the pharmacokinetic behavior of 14C-poly (methylmethacrylate) nanoparticles in experimental tumor models Pharm. Res. 18 2001 1613 1619 (Pubitemid 33022419)
432. J.C. Olivier, C. Vauthier, M. Taverna, F. Puisieux, D. Ferrier, and P. Couvreur Stability of orosomucoid-coated polyisobutylcyanoacrylate nanoparticles in the presence of serum J. Control. Release 40 1996 157 168 (Pubitemid 26238368)
433. J. Kreuter, D. Shamenkov, V. Petrov, P. Ramge, K. Cychutek, C. Koch-Brandt, and R. Alyautdin Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier J. Drug Target. 10 2002 317 325 (Pubitemid 34746313)
434. H. Wang, and R.H. Eckel What are lipoproteins doing in the brain? Trends Endocrinol. Metab. 25 2014 8 14
435. G.S. Getz, and C.A. Reardon Apoprotein E as a lipid transport and
436. A. Zensi, D. Begley, C. Pontikis, C. Legros, L. Mihoreanu, S. Wagner, C. Buchel, H. von Briesen, and J. Kreuter Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones J. Control. Release 137 2009 78 86
437. M. Kanehisa, S. Asayama, and H. Kawakami Design of lipoprotein-adsorbed liposomes retaining Mn-porphyrins for SOD mimic delivery to brains Desalin. Water Treat. 17 2010 31 36
438. A.V. Kabanov, S.V. Vinogradov, Y.G. Suzdaltseva, and V. Alakhov Water-soluble block polycations as carriers for oligonucleotide delivery Bioconjug. Chem. 6 1995 639 643
439. A. Harada, and K. Kataoka Chain length recognition: core-shell supramolecular assembly from oppositely charged block copolymers Science 283 1999 65 67 (Pubitemid 29044846)
440. A. Perico, and A. Ciferri The supramolecular association of polyelectrolytes to complementary charged surfactants and protein assemblies Chemistry 15 2009 6312 6320
441. H.K. Nguyen, P. Lemieux, S.V. Vinogradov, C.L. Gebhart, N. Guerin, G. Paradis, T.K. Bronich, V.Y. Alakhov, and A.V. Kabanov Evaluation of polyether-polyethyleneimine graft copolymers as gene transfer agents Gene Ther. 7 2000 126 138 (Pubitemid 30088959)
442. G.D. Zhang, A. Harada, N. Nishiyama, D.L. Jiang, H. Koyama, T. Aida, and K. Kataoka Polyion complex micelles entrapping cationic dendrimer porphyrin: effective photosensitizer for photodynamic therapy of cancer J. Control. Release 93 2003 141 150 (Pubitemid 37421356)
443. M. Jaturanpinyo, A. Harada, X. Yuan, and K. Kataoka Preparation of bionanoreactor based on core-shell structured polyion complex micelles entrapping trypsin in the core cross-linked with glutaraldehyde Bioconjug. Chem. 15 2004 344 348 (Pubitemid 38365194)
444. T.K. Bronich, T. Cherry, S.V. Vinogradov, A. Eisenberg, V.A. Kabanov, and A.V. Kabanov Self-assembly in mixtures of poly(ethylene oxide)-graft- poly(ethyleneimine) and alkyl sulfates Langmuir 14 1998 6101 6106 (Pubitemid 128612934)
445. T.K. Bronich, A.V. Kabanov, V.A. Kabanov, K. Yu, and A. Eisenberg Soluble Complexes from Poly(ethylene oxide)-block-polymethacrylate Anions and N-Alkylpyridinium Cations Macromolecules 30 1997 3519 3525 (Pubitemid 127569542)
446. T.K. Bronich, A. Nehls, A. Eisenberg, V.A. Kabanov, and A.V. Kabanov Novel drug delivery systems based on the complexes of block ionomers and surfactants of opposite charge Colloids Surf. B: Biointerfaces 16 1999 243 251 (Pubitemid 29486811)
447. T.K. Bronich, A.M. Popov, A. Eisenberg, V.A. Kabanov, and A.V. Kabanov Effects of block length and structure of surfactant on self-assembly and solution behavior of block ionomer complexes Langmuir 16 2000 481 489 (Pubitemid 32211241)
448. S.V. Solomatin, T.K. Bronich, T.W. Bargar, A. Eisenberg, V.A. Kabanov, and A.V. Kabanov Environmentally responsive nanoparticles from block ionomer complexes: effects of ph and ionic strength Langmuir 19 2003 8069 8076
449. S.V. Solomatin, T.K. Bronich, A. Eisenberg, V.A. Kabanov, and A.V. Kabanov Colloidal stability of aqueous dispersions of block ionomer complexes: effects of temperature and salt Langmuir 20 2004 2066 2068
450. T. Yusa, J.D. Crapo, and B.A. Freeman Liposome-mediated augmentation of brain SOD and catalase inhibits CNS O2 toxicity J. Appl. Physiol. Respir. Environ. Exerc. Physiol. 57 1984 1674 1681 (Pubitemid 15191362)
451. D.S. Manickam, A.M. Brynskikh, J.L. Kopanic, P.L. Sorgen, N.L. Klyachko, E.V. Batrakova, T.K. Bronich, and A.V. Kabanov Well-defined cross-linked antioxidant nanozymes for treatment of ischemic brain injury J. Control. Release 162 2012 636 645
452. A. Gaydess, E. Duysen, Y. Li, V. Gilman, A. Kabanov, O. Lockridge, and T. Bronich Visualization of exogenous delivery of nanoformulated butyrylcholinesterase to the central nervous system Chem. Biol. Interact. 187 2010 295 298
453. N.L. Klyachko, D.S. Manickam, A.M. Brynskikh, S.V. Uglanova, S. Li, S.M. Higginbotham, T.K. Bronich, E.V. Batrakova, and A.V. Kabanov Cross-linked antioxidant nanozymes for improved delivery to CNS Nanomedicine 8 2012 119 129
454. E.G. Rosenbaugh, J.W. Roat, L. Gao, R.F. Yang, D.S. Manickam, J.X. Yin, H.D. Schultz, T.K. Bronich, E.V. Batrakova, A.V. Kabanov, I.H. Zucker, and M.C. Zimmerman The attenuation of central angiotensin II-dependent pressor response and intra-neuronal signaling by intracarotid injection of nanoformulated copper/zinc superoxide dismutase Biomaterials 31 2010 5218 5226
455. H. Dou, C.J. Destache, J.R. Morehead, R.L. Mosley, M.D. Boska, J. Kingsley, S. Gorantla, L. Poluektova, J.A. Nelson, M. Chaubal, J. Werling, J. Kipp, B.E. Rabinow, and H.E. Gendelman Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery Blood 108 2006 2827 2835
456. N.L. Klyachko, M.J. Haney, Y. Zhao, D.S. Manickam, V. Mahajan, P. Suresh, S.D. Hingtgen, R.L. Mosley, H.E. Gendelman, A.V. Kabanov, and E.V. Batrakova Macrophages offer a paradigm switch for CNS delivery of therapeutic proteins Nanomedicine (London) 2013 Nov 18 [Epub ahead of print]
457. M.J. Haney, Y. Zhao, E.B. Harrison, V. Mahajan, S. Ahmed, Z. He, P. Suresh, S.D. Hingtgen, N.L. Klyachko, R.L. Mosley, H.E. Gendelman, A.V. Kabanov, and E.V. Batrakova Specific transfection of inflamed brain by macrophages: a new therapeutic strategy for neurodegenerative diseases PLoS ONE 8 2013 e61852
458. M.J. Haney, P. Suresh, Y. Zhao, G.D. Kanmogne, I. Kadiu, M. Sokolsky-Papkov, N.L. Klyachko, R.L. Mosley, A.V. Kabanov, H.E. Gendelman, and E.V. Batrakova Blood-borne macrophage-neural cell interactions hitchhike on endosome networks for cell-based nanozyme brain delivery Nanomedicine (London) 7 2012 815 833
459. Y. Zhao, M.J. Haney, V. Mahajan, B.C. Reiner, A. Dunaevsky, R.L. Mosley, A.V. Kabanov, H.E. Gendelman, and E.V. Batrakova Active targeted macrophage-mediated delivery of catalase to affected brain regions in models of Parkinson's disease J. Nanomed. Nanotechnol. S4 2011
460. Y. Zhao, M.J. Haney, N.L. Klyachko, S. Li, S.L. Booth, S.M. Higginbotham, J. Jones, M.C. Zimmerman, R.L. Mosley, A.V. Kabanov, H.E. Gendelman, and E.V. Batrakova Polyelectrolyte complex optimization for macrophage delivery of redox enzyme nanoparticles Nanomedicine (London) 6 2011 25 42
461. M.J. Haney, Y. Zhao, S. Li, S.M. Higginbotham, S.L. Booth, H.Y. Han, J.A. Vetro, R.L. Mosley, A.V. Kabanov, H.E. Gendelman, and E.V. Batrakova Cell-mediated transfer of catalase nanoparticles from macrophages to brain endothelial, glial and neuronal cells Nanomedicine (London) 6 2011 1215 1230
462. A.M. Brynskikh, Y. Zhao, R.L. Mosley, S. Li, M.D. Boska, N.L. Klyachko, A.V. Kabanov, H.E. Gendelman, and E.V. Batrakova Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson's disease Nanomedicine (London) 5 2010 379 396
463. Y. Zhao, M.J. Haney, N.L. Klyachko, S. Li, S.L. Booth, S.M. Higginbotham, J. Jones, M.C. Zimmerman, R.L. Mosley, A.V. Kabanov, H.E. Gendelman, and E.V. Batrakova Polyelectrolyte complex optimization for macrophage delivery of redox enzyme nanoparticles Nanomedicine (London, England) 6 2011 25 42
464. Y. Zhao, M.J. Haney, V. Mahajan, B.C. Reiner, A. Dunaevsky, R.L. Mosley, A.V. Kabanov, H.E. Gendelman, and E.V. Batrakova Active targeted macrophage-mediated delivery of catalase to affected brain regions in models of Parkinson's disease J. Nanomed. Nanotechnol. 2011 Sep 10 S4. pii: 003
465. M.J. Haney, Y. Zhao, S. Li, S.M. Higginbotham, S.L. Booth, H.Y. Han, J.A. Vetro, R.L. Mosley, A.V. Kabanov, H.E. Gendelman, and E.V. Batrakova Cell-mediated transfer of catalase nanoparticles from macrophages to brain endothelial, glial and neuronal cells Nanomedicine (London, England) 6 2011 1215 1230
466. M.J. Haney, P. Suresh, Y. Zhao, G.D. Kanmogne, I. Kadiu, M. Sokolsky-Papkov, N.L. Klyachko, R.L. Mosley, A.V. Kabanov, H.E. Gendelman, and E.V. Batrakova Blood-borne macrophage-neural cell interactions hitchhike on endosome networks for cell-based nanozyme brain delivery Nanomedicine (London, England) 7 2012 815 833
467. E.V. Batrakova, H.E. Gendelman, and A.V. Kabanov Cell-mediated drug delivery Expert Opin. Drug Deliv. 8 2011 415 433